{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "fe300c1c6130a4c2547558bc42ad1f1e",
    "title": "Jefferies",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/Jefferies/Slides Menin for 7M Insulin-deficient Diabetes - Initiate at Buy PT 5Slides Menin for 7M Insulin-deficient Diabetes - In_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:21:33.123031",
      "extracted_at": "2025-10-26T12:21:33.123040"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 52,
        "successful_pages": 52,
        "date": "2025-08-28",
        "publication": "25.9月 普通个人版/9.1 普通个人版/Jefferies",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 11,
          "reduction_ratio": 0.06958244324109497
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/Jefferies"
      }
    }
  },
  "passages": [
    {
      "passage_id": "3c60e3e77076ad2f",
      "text": "Equity ResearchAugust 28,2025",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5c828c11ec117b15",
      "text": "*Slides* Menin for ~7M insulin-deficient Diabetes - Initiate at BUy; PT &#36;5",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ea441a74081a1550",
      "text": "BMEA is a clinical-stage biotech focused on developing oral small molecule for diabetes and obesity medicines. BMEA's lead asset, icovanemib (covalent menin inhibitor), is being studied in both Type 2 Diabetes (T2D) and Type 1 Diabetes (T1D), with Ph2 data updates in 2H25, and has an MOA that could fundamentally address a root driver of diabetes. We model peak adjusted revenues of ~&#36;750M, driven by BMEA's T2D franchise. Thus, we initiate at Buy with PT of &#36;5.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "bee557819b105354",
      "text": "**Bottom line.** BMEA is developing a differentiated oral menin inhibitor that has the potential to address a key driver of T2D and be a disruptor in a large disease space that has had little innovation beyond maintenance Tx. Recent POC data from the COVALENT-111 study showed promising HbA1c reduction and C-peptide production data at 26W, especially for a large subpopulation of underserved patients with SIDD (severely insulin-deficient diabetes), after a 12W oral dosing regimen. The upcoming 3Q25 52W readout will help answer icovanemib's durability and long-term safety, potentially attractive to partnership. We estimate ~&#36;750M in peak adjusted revenues for the Ico T2D program. Co has ~&#36;60M in cash with runway into 2H26.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5a2f877b3e7f2d6d",
      "text": "**Rating/ valuation:** We initiate coverage with Buy rating and have DCF-based PT of &#36;5, including ~&#36;3 for icovanemib in T2D, ~&#36;1.5 for pipeline / platform, and ~&#36;0.5 in cash.**Icovanemib has the potential to become an innovative functional Tx for a large subcategory of T2D and beyond. On mechanism,** ico is a covalent menin inhibitor that can promote beta cell proliferation and improve beta cell function to address an underlying diabetes driver. **On efficacy,** BMEA has generated promising clinical data in T2D pts via a Ph2 which showed particular HbA1c reduction and C-peptide production in SIDD pts (N=7-23). **On safety,** at 26W, ico has been well-tolerated with no TEAE-driven study DC, no clinically sig elevations in ALT/ AST, nor any Tx-emergent hypoglycemia. **On market opportunity,** SIDD is a large market, with ~7.6M U.S. pts who have few options beyond insulin and other maintenance Tx. Ico is leading in menin inhibitor for T2D/GLP1 combo. With ico mechanistically enhancing GLP1R and insulin expression and showing synergistic preclinical/clinical,efficacy data, Co plans to run a Ph2 12W/26W study (~40 pts in combo vs. ~20 GLP1 alone)⁹⁰ 2H25 in GLP1-failed HbA1c uncontrolled T2D pts, with initial data likely in 2H26, expanding market potential into insulin-resistant T2D pts and addressing GLP1 compliance issue by lowering GLP1 dose. **T1D.** Co expects to report 52W data from Ph2 in 2H25 to support next stage, likely via partnership.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4b2d898a9a3383fd",
      "text": "**BMEA's pipeline also includes an oral small molecule GLP-1RA, BMF-650, which is designed** **with improved pharmacological properties, including PK and BA.** Supported by robust preclinical efficacy safety data, BMEA expects to enroll its first patient for a clinical trial evaluating BMF-650 in 4Q25, with top-line SAD/MAD 4W data likely in 1H26.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d9a591664cf37d6d",
      "text": "FY (Dec)See Full Report for Details.2028E2025E2026E2027EEPS0.000.000.000.00Rev. (MM)1.70.91.00.6EV/Rev36.0x68.8x65.2x99.4x",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ae417f4a8686a439",
      "text": "INITIATING COVERAGERATINGBUYPRICE&#36;1.86*PRICE TARGET|% TO PT&#36;5.00|+169%52W HIGH-LOW&#36;13.07-&#36;1.29FLOAT (%)|ADV MM (USD)67.7%|1.24MARKET CAP&#36;111.6MTICKERBMEA",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "69371443292c0f4c",
      "text": "*Prior trading day's closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f1e9152d00742fd1",
      "text": "FY (Dec)CHANGE TO JEFeJEF vs CONS202520262025202620252026REVNANANANANANAEPSNANANANANANA selections",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e4ef58b399739b34",
      "text": "2025 ($)Q1Q2Q3Q4FYEPS0.000.000.000.000.0",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "56de84924461329f",
      "text": "**Liang Cheng, Ph.D. * | Equity Associate**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "20d2dcddcdefae7d",
      "text": "**Fiona Jia, Ph.D. * | Equity Associate**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "68166f2ae0dbe709",
      "text": "**Nabeel Nissar * | Equity Associate**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "12ad780b20435d7a",
      "text": "Chart 1 - BMEA's Pipeline and Key Upcoming Catalysts",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "877088b30e059c7a",
      "text": "ProgramMOAIndicationStageEventTimingIcovamenibMenin inhibitorT2DPh2Ph2 52-week follow up data release2H25 (likely Sept)IcovamenibMenin inhibitorT1DPh2Ph2 52-week topline data release2H25 (likely Sept/ Oct)Icovamenib + GLP-1 TxMenin inhibitor + GLP-1T2DPh2 readyPh2 initiation2H25 (likely Sept/ Oct)BMF-650GLP-RAObesityPre-clinicalPh1 initiation2H25 (likely 4Q)",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b42d42d0995696e1",
      "text": "Source: Company reports and Jefferies research",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4d862b6c6ed00624",
      "text": "BMEA is developing oral small molecule medicines for daptes and obesity that could fundamentally address key drivers of disease. BMEA's lead asset, icovanemib (covalent menin inhibitor), is currently being studied in both T2D and T1D but also has the potential to be used with GLP- 1 Tx in T2D/obesity. We see icovanemib as a potential disruptor in T2D, a large disease space that has not had much innovation beyond maintenance therapies, especially backed by recent POC data from the COVALENT- 111 study.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3f1ee774ad30896f",
      "text": "Base Case, \\(5, + 169\\%\\)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "d2eeacbf39ea9afc",
      "text": "- Icovanemib US adjusted peak sales in T2D: \\(\\sim\\) \\(735M\\) (POS \\(15\\%\\) )- Platform and pipeline value: \\(100M\\) - Price target: \\(5\\) (DCF-based)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3a4c3243191dd6f5",
      "text": "Upside Scenario, \\(18, + 868\\%\\)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cf11fd60f733fc1e",
      "text": "- Icovanemib US adjusted peak sale in T2D: \\(\\sim\\) \\(1.2B\\) (POS \\(25\\%\\) )- Platform and pipeline value: \\(100M\\) - Price target: \\(18\\) (DCF-based)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3b09bc6a48a21dee",
      "text": "Downside Scenario, \\(0.5, - 73\\%\\)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "732fa86d0239da9e",
      "text": "- Icovanemib fails in T2D; US adjusted peak sale in T2D: \\(\\sim\\) \\(50\\) - Cash runway: \\(65.6M\\) - Price target: \\(0.5\\) (2Q25 cash runway per share)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "d4e96f18e53bdb5b",
      "text": "Top material issue(s): 1) Product Quality & Safety: As a biopharmaceutical company focused on developing a novel therapeutic for type 2 diabetes that affects the cell cycle, BMEA will need to ensure safety of the product and monitor patient safety in and beyond clinical trials. 2) Access & Affordability: With many approved products for type 2 diabetes (including many generics), BMEA will need to carefully balance potential access and profitability of BMF- 219, if approved and marketed, based on the true benefit to patients.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "7bda72cde2d83085",
      "text": "Qs to Mgmt: 1) What are you doing to ensure that clinical trials enroll patients with diverse backgrounds? 2) Does BMEA have, or have plans to implement, an oversight committee to track its ESG efforts? 3) Please describe what plans BMEA has in place to promote environmental stewardship in its operations over the next 5 years. 4) How will you monitor potential tumorigenesis resulting from BMF- 219's mechanism of action to ensure the long- term safety of patients who have plentiful alternative treatment options for a chronic condition?",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "fb322757df0ae8aa",
      "text": "ESG Sector Deep Dive: Link",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1ee0eaa8d3bfc239",
      "text": "BMEA DCF Analysis (1M)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "d7915f1dd34f72e7",
      "text": "Pre- clinical data for menin inhibition in T2D Efficacy and safety data for Icovamenib in T2D Market opportunity for Icovamenib",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "5e50affde12b5c6e",
      "text": "Background information",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "965deed71a6c0449",
      "text": "Corporate Information",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a83231b5f0d5592d",
      "text": "BMEA is a clinical stage biotech focused on developing oral small molecule medicines for diabetes and obesity. BMEA's lead asset, icovamenib (covalent menin inhibitor), is currently being studied in both Type 2 Diabetes (T2D) and Type 1 Diabetes (T1D), and has the potential to be an oral disease- modifying therapy that improves beta cell function and promotes beta cell regeneration by inhibiting menin. Icovamenib's MOA enables it to potentially restore the body's natural ability to regulate blood sugars. BMEA has reported promising Ph2a topline data for icovamenib in T2D patients, especially the subcategory of patients with severe insulin- deficient diabetes (SIDD) and expects to provide 52- week follow up data for this study likely in 3Q25. Beyond diabetes, BMEA is planning to evaluate icovamenib in conjunction with a GLP- 1 based therapy for T2D/ obesity and evaluate their oral GLP- 1RA, BMF- 650 in obesity. We model peak adjusted revenues of \\(\\sim \\$ 750M\\) , driven by BMEA's T2D franchise. Thus, we initiate at Buy with PT of \\(\\) 5\\$ .",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "97fd8a728c784ab5",
      "text": "Bottom line. BMEA is developing a differentiated oral menin inhibitor that has the potential to fundamentally address a key driver of T2D. We see icovamenib as a potential disruptor in a large disease space that has not had much innovation beyond maintenance therapies. Recent proof- of- concept data coming out of the COVALENT- 111 study showed promising HbA1c reduction and C- peptide production data at week 26, especially for a subpopulation of underserved patients with SIDD, after a 12- week oral dosing regimen. The upcoming 52- week data readout will provide further insights on key questions surrounding icovamenib's durability and long- term safety. We estimate \\(\\sim \\$ 750M\\) in peak adjusted revenues for the Icovamenib T2D program with \\(\\sim \\$ 100M\\) for BMEA's platform/ pipeline. Co has \\(\\sim \\$ 60M\\) in cash with runway into 2H26. Rating/ valuation. We initiate coverage with Buy rating and have DCF- based PT of \\(\\) 5\\(, including \\(\\sim\\) \\(\\) 3\\(for Icovamenib in T2D, \\(\\sim\\)\\) 1.5 for pipeline / platform, and \\(\\sim\\) \\(\\) 0.5\\(for cash.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e61756f0d7f63f8e",
      "text": "Icovamenib has the potential to become an innovative functional cure for a large subcategory of T2D and beyond. On mechanism, icovamenib is a covalent menin inhibitor that can promote beta cell proliferation and improve beta cell function to address an underlying disease driver. On efficacy, BMEA has generated promising clinical data in T2D patients via its COVALENT- 111 Ph2 study which showed particular HbA1c reduction and C- peptide production in the SIDD subpopulation. On safety, at 26 weeks, icovamenib has been well- tolerated with no TEAE- driven study discontinuations, any clinically significant elevations in aminotransferases, nor any treatment- emergent hypoglycemia. On market opportunity, the SIDD subpopulation of T2D is a large market, with \\(\\sim 7.6M U.S.\\) patients who have few options beyond insulin and other maintenance therapies. GLP1 combo. With icova mechanistically enhancing GLP1R and insulin expression and showing synergistic preclinical/ clinical efficacy data, Co plans to run a Ph2 12W/ 26W study ( \\(\\sim 40\\) pts in combo vs. \\(\\sim 20\\) GLP1 alone) in 2H25 in GLP1 failed HbA1c uncontrolled T2D pts, with initial data likely in 2H26, expanding market potential into insulin- resistant T2D pts and addressing GLP1 compliance issue by lowering GLP1 dose. T1D. Co expects to report 52W data from Ph2 in 2H25 to support next steps likely via partnership.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "9017f9a301d483b2",
      "text": "BMEA's pipeline also includes an oral small molecule GLP- 1RA, BMF- 650, which is designed with improved pharmacological properties including PK and BA. Supported by robust preclinical efficacy/ safety data, BMEA expects to enroll its first patient for a clinical trial evaluating BMF- 650 in 4Q25, with topline SAD/ MAD 4W data likely in 1H26.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "855b592db6d5a3e7",
      "text": "Program/ AssetRoute of AdminPre-ClinicalPhase IPhase IIPhase IIIGlobal RightsNext Milestone in 2H 2025Icovamenib Potential First-in-Class Oral Menin Inhibitor Monotherapy with combo potentialOralType 2 DiabetesCOVALENT-111 - T2D ongoingType 2 Diabetes - Severe Insulin DeficiencyCOVALENT-211 - T2D plannedType 2 Diabetes - Combo Study with GLP-1 - RACOVALENT-212 - T2D plannedBMF-650 Potential Best-in-Class Oral GLP-1 RA MonotherapyOralObesity/ Type 2 DiabetesIND Enabling Studies",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "8bea9619895c5911",
      "text": "ProgramMOAIndicationStageEventTimingIcovamenibMenin inhibitorT2DPh2Ph2 52-week follow up data release2H25 (likely Sept)IcovamenibMenin inhibitorT1DPh2Ph2 52-week topline data release2H25 (likely Sept/ Oct)Icovamenib + GLP-1 TxMenin inhibitor + GLP-1T2DPh2 readyPh2 initiation2H25 (likely Sept/ Oct)BMF-650GLP-RAObesityPre-clinicalPh1 initiation2H25 (likely 4Q)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "ab6d3d3740c4bb91",
      "text": "Source: Company reports and Jefferies research",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "8f4a89d6801a4a93",
      "text": "Icovamenib 52- week data readout in T2D in 2H25 (likely Sept, with database recently locked; potentially detailed data at EASD25 Sept/ ATTD26 March)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4a8aa866cea2adc9",
      "text": "Potential outcome: durable reduction in HbA1c levels in treated SIDD patients vs pbo, sustained production of C- peptide in treated SIDD patients that is higher than that seen in pbo group patients, no new safety signals; pt N will likely be smaller with some pts dropping out of long- term follow- up (hard to keep pts on study without Tx); will be interesting to see the difference between Arm B (QD 100mg 12wks) and Arm C (QD 100mg 8wks + BID 100mg 4wks",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "65ea1c222d1baa1f",
      "text": "Stock change upside case: \\(+ \\sim 30 - 50\\%\\) with \\(\\sim 40\\%\\) probability",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "37c35df69c56002d",
      "text": "Stock change downside case: \\(\\sim 10 - 30\\%\\) with \\(\\sim 60\\%\\) probability",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8bb1ea1bbf21f794",
      "text": "Next Steps: FDA feedback on path forward by YE25, with key topics being: 1) to get alignment with the FDA on SIDD subpopulation [young onset, normal BMI, high HbA1c, low HOMA- B] for Ph2b); 2) next study (likely Ph2b vs. Ph3) and N; 3) dose selection; 4) study duration (Tx [likely 12wks] vs. follow- up [likely 1yr]; likely one regimen vs. repeat regimen); 5) endpoints",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4ef64d8b691948b0",
      "text": "Potential outcome: proof of concept to show reduction in HbA1c levels and C- peptide production; no new safety signals; pt N likely small given clinical hold",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f26117c14f316c5d",
      "text": "Stock change upside case: \\(+ \\sim 10 - 30\\%\\) with \\(\\sim 25\\%\\) probability",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "d20c46cd4c11b4cc",
      "text": "Stock change downside case: \\(\\sim 5 - 10\\% +\\) with \\(\\sim 75\\%\\) probability.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "1ce2d6a7d114001b",
      "text": "Next Steps: IST to generate more data quickly (current cash not funding T1D); will assess the need for immunosuppressant (depending on the level of beta cell proliferation needed for sufficient insulin production); likely early stage 2- 3 pts",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "b632d0682c1c2b19",
      "text": "- Clinical Risks: As with all companies in biotechnology that are investing in the development of clinical programs, trial failures and regulators requesting additional and unexpected new studies prior to approving marketing applications can lead to delays in time to market entry and could also possibly result in the discontinuation of programs. Positive study results are needed to support U.S. approvals of any of BMEA's product candidates. All of BMEA's pipeline products are early-stage and there is no guarantee that future trials will demonstrate positive efficacy or acceptable safety profile in pivotal studies, although various preclinical studies and early clinical trials have shown promising efficacy/safety results.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "1b7d12cfb1726145",
      "text": "- Regulatory Risks: The FDA/EMA could determine that the marketing application(s) for any of BMEA's clinical candidates is/are inadequate and could delay/deny approval(s). Any delays in approval timelines could impact our earnings estimates, price target, and/or rating. Even if results from clinical studies are positive, the FDA may not approve those assets due to various issues, such as CMC, and/or require additional pre-clinical/clinical studies. Even if pivotal studies are positive, the EMA may not opt to approve those product candidates and require additional studies.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "c62f5657c554be41",
      "text": "- Commercial and Competitive Risks: Our estimates primarily rely on future sales of Icovamenib and there is no guarantee BMEA and/or its potential pharmaceutical/biotechnology partners will be successful marketing in the T2D market, which has no true disease modifying disease. Our estimates rely on the success of BMEA to receive drug reimbursement from both private and public payors. It is currently unclear how restrictively payors would cover those product candidates when/if approved, especially given long-standing and inexpensive alternatives in the diabetes space (e.g. insulin).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "25cc806aaa1e110e",
      "text": "- Financing Risks: BMEA has spent significant R&D to advance current pipeline programs, although current cash should be sufficient to fund operations into 2H26. If BMEA opts to advance Icovamenib into late clinical trials, Co may require potentially dilutive financing via secondary stock offerings or debt.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "8c09fdd4ecf48282",
      "text": "- What pre-clinical data support MOA of menin inhibition for Type 2 Diabetes treatment?",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "bd811f09dae5f92d",
      "text": "- What efficacy and safety data support the further development of Icovamenib in Type 2 Diabetes?",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "73dd40108f038610",
      "text": "- What is the market opportunity for Icovamenib?",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "670e224de837f771",
      "text": "- How much value does BMEA's earlier pipeline hold?",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "17bbbd6296316ef8",
      "text": "- Icovamenib (BMF-219) is a covalent menin inhibitor that can enable beta cell proliferation and improve beta cell function to treat an underlying disease driver- Menin is a protein that not only suppress beta cell growth and replication in pancreatic beta cells by repressing genes involved in cell cycle progression but also represses genes that are involved in insulin production- Through its covalent binding, icovamenib forms an irreversible bond with menin which helps with durable inhibition ( \\(\\sim 40\\%\\) vs. \\(\\sim 100\\%\\) ; thus less concern on on-target tox such as neuroendocrine function) and sustained therapeutic effects- Covalent binding allows icovamenib to be used at lower doses and be dosed less frequently; however, it's worth watching for long-term safety, especially for use in chronic diseases, such as T1D/ T2D",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "82d56fcb65aeecba",
      "text": "In both T1D and T2D, loss of beta cell mass and subsequent decrease in insulin production are manifestations and drivers of disease",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "153dc080e485956b",
      "text": "In T1D, autoimmune attacks on beta cells killing off insulin- producing beta cells that result in patients becoming dependent on insulin- In T2D, patients' beta cells produce more insulin given decreased insulin sensitivity and beta cells eventually exhaust and die off leading to progressive decline in beta cell function and numbers over the course of T2D",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "01ecc0352ed73b27",
      "text": "Menin Inhibition in Diabetes",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "b3944c029ccaa532",
      "text": "- The connection between menin inhibition and beta cell proliferation has been noted in pregnant women who have shown an enlargement of islets from beta cell proliferation in part due to the action of placental hormones through the prolactin receptor through engaging with menin, among other genes",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "8aa70820d35e72c5",
      "text": "- In Zucker Diabetic Fatty (ZDF) rat models for T2D, icovamenib (BMF-219) has also been shown to restore glycemic control over a 4-week dosing study with a significant reduction in fasting blood glucose level that was responsive to an oral glucose tolerance test (OGTT)",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "bb7e96a12e87c70b",
      "text": "4-hr Fasting Blood Glucose",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "f01b988e5544f079",
      "text": "2-hr post-OGTT glucose",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "a3eb992650006ef6",
      "text": "In another pre- clinical study in which ZDF rates were dosed daily with BMF- 219 for 2 weeks before a 2- week wash out period, treated rats saw a significant decrease in fasting blood glucose coupled with a significant increase in fasting insulin and c- peptide levels compared to controls",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "a1c78b260eed8844",
      "text": "It is interesting to note that BMF- 219 treated mice had significantly lower levels of fasting insulin and c- peptide levels right after dosing, at 2 weeks, compared to controls, which provides insight into BMF- 219's MOA that first improves insulin sensitivity during dosing before then acting to promote beta cell proliferation that takes more time to act",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "45fdf3da5ccc8e96",
      "text": "BMF-219 Treatment on Blood Glucose, Insulin, C-Peptide in ZDF Rats",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "564e59b0425125a3",
      "text": "- ZDF rats treated with BMF-219 had an increase in beta cell area from a quantitative analysis of pancreatic islet tissue post-dosing, providing support for BMF-219's MOA of promoting beta cell regeneration and proliferation. In contrast, controls saw a notable decrease in beta cell area over time",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "6547eba2ab38b7b0",
      "text": "- BMF-219 treated ZDF rats also demonstrated strong beta cell function, as measured by HOMA-Beta, even two weeks post-dosing cessation vs controls",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "a0244c53bca7ca68",
      "text": "Beta Cell Area (IHC - Insulin)",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "31b5607ae7d4bc20",
      "text": "Beta Cell Function (at Day 31)",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "978a43cff56a78ec",
      "text": "- What pre-clinical data support MOA of menin inhibition for Type 2 Diabetes treatment?",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "f9398119f1377fb9",
      "text": "- What efficacy and safety data support the further development of Icovamenib in Type 2 Diabetes?",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "c4602264b2e87cfc",
      "text": "- What is the market opportunity for Icovamenib?",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "550fb86c78b1e831",
      "text": "- How much value does BMEA's earlier pipeline hold?",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "06171ce6ec336292",
      "text": "In a Ph2a placebo- controlled study in \\(n = 216\\) T2D patients \\((N = 165\\) per protocol with 1+ antihyperglycemic agents; 115 active vs. 50 pbo), icovamenib demonstrated a promising decrease in HbA1c from baseline at week 26, hitting its primary efficacy endpoint",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "3e75e8125e46af52",
      "text": "In pts with pre- specified severe insulin- deficient diabetes (SIDD) icovamenib combined 3 different dosing regimens \\((N = 12 / 7 / 4\\) Arm A/B/C vs. 11 pbo) reached a non- stat sig decrease in HbA1c from baseline at week 26 vs. pbo",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "6063216e0a770480",
      "text": "In one dosing regimen group (Arm B: QD 12wks; unclear why better than Arm C [QD 8wks + BID 4wks], likely small N and pt baseline [lessmetformin monoTx in Arm B suggesting more severe pts), icovamenib showed a stat sig \\(\\sim 1.3\\%\\) decrease in HbA1c from baseline at week 26 vs \\(\\sim 0.2\\%\\) increase placebo group, demonstrating icovamenib's ability to significantly improve blood glucose control over several months",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "2b52b57299d7ba31",
      "text": "Similarlv. in overall per protocol population \\((N = 115 / 45 / 37 / 33)\\) active vs. 50 pbo). Arm B achieved stat sia. but Arm A/ C did not Participants with Pre- specified Severe Insulin- Deficient Diabetes",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "ab3af51ad155f5a2",
      "text": "Mean Change in HbA1c Over Time",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "3b1d6cbbbfdf603e",
      "text": "Arm A, B, and C \\((n = 23\\) Active; \\(n = 11\\) Placebo)",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "0951a05b50045471",
      "text": "Arm B \\((n = 7\\) Active; \\(n = 11\\) Placebo)",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "9477bcc6cc7c1158",
      "text": "Arm A: 8 weeks of dosing 100mg QD; Arm B: 12 weeks of dosing 100 mg QD; Arm C: 8 weeks of 100 mg QD + 4 weeks of 100 BID",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "3b9eae46c1f85114",
      "text": "Clinical data – efficacy vs approved Tx",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "de9e97eaf3c1a208",
      "text": "- Icovamenib's Ph2a HbA1c efficacy data of pbo-adj ~1.5% mean HbA1c reduction at week 26 is on par with that of most currently approved T2D therapies",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "27bbeadc773c71aa",
      "text": "- Ozempic (GLP-1 agonist) has reported mean HbA1c change of -1.5% at its highest 1mg dose at week 30, Jardiance (SGLT2 inhibitor) has reported mean change of -0.9% at highest 25mg dose at week 24, and Januvia (DPP4 inhibitor) has reported mean change of -0.8% at 199mg dose at week 24",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "ad2a35784992f5b2",
      "text": "- Icovamenib is differentiated based on its disease-modifying MOA, its convenient oral ROA, and its lack of need for chronic dosing",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "3f1381db70001e01",
      "text": "Icovamenib vs Currently Approved T2D Therapies",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "db1a69d2af66a97e",
      "text": "TherapyDosing RegimenAdministration RouteObservation PeriodMean HbA1c Reduction (placebo adj. %)ICOVAMENIB (Menin Inhibitor)12 WeeksOralWeek 26-1.5% (100mg)Ozempic (GLP 1 Agonist)Chronic DosingInjectableWeek 30-1.2 (0.5mg)-1.5 (1mg)Mounjaro (GLP-1/GIP Agonist)Chronic DosingInjectableWeek 40-1.7 (5mg)-1.6 (15mg)Jardiance (SGLT2 Inhibitor)Chronic DosingOralWeek 24-0.7 (10mg)-0.9 (25mg)Januvia (DPP4 Inhibitor)Chronic DosingOralWeek 24-0.8 (100mg)",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "da8dc37b514de13d",
      "text": "In the Ph2a trial, icovamenib also demonstrated an increase in insulin secretion, as measured by C- peptide levels, but only in SIDD pts and not in insulin- resistant T2D patients",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "751603d2c4f7fcfb",
      "text": "In SIDD trial patients \\((n = 23)\\) across all dose regimens tested, icovamenib showed an increase in C- peptide change compared to baseline",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "c55d87741530b649",
      "text": "The lack of increase in C- peptide levels in insulin- resistant T2D patients is likely due to internal negative feedback loops that prevent overproduction of C- peptide, given that insulin- resistant T2D patients already produce more than enough C- peptide and need a therapy that allows the body to use that insulin better",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "1e7650731023d206",
      "text": "While there was no increase in C- peptide levels in insulin- resistant T2D patients, we would have liked to see other markers presented on evidence of beta cell proliferation and beta cell mass increase to see further support for icovamenib's MOA",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "47d411347410ce8c",
      "text": "Insulin- deficient patients demonstrated increase in C- peptide over 24 weeks",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "184ff4598cef9738",
      "text": "Insulin- resistant patients did not demonstrated increase in C- peptide over 24 weeks",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "4af16b10dbe5db6f",
      "text": "In the Ph2a trial, icovamenib showed an increase of \\(53\\%\\) in C- peptide change compared to baseline across all dosing regimens, whereas the placebo group only showed a \\(7\\%\\) increase",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "770fa0dbd7f888b7",
      "text": "While HbA1c changes can be influenced by several external factors (e.g. better glycemic control due to increased vigilance in diabetes management from being in a clinical trial), C- peptide change provides evidence of icovamenib' MOA and a more objective measure of icovamenib's therapeutic potential for diabetes patients",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "a4c025a88f83fe15",
      "text": "Pre-specified Patients with Severe Insulin-Deficient Diabetes C-peptide Index Change from Baseline During OGTT",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "d51a932528cae210",
      "text": "In the 26- week Ph2a trial, icovamenib demonstrated a tolerable safety profile with \\(26\\%\\) of treated pts across all dose regimens (n- 200) reporting \\(\\geq 1\\) TEAEs vs \\(28\\%\\) in n=67 patients in the placebo group",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "f95666f8c7c06c63",
      "text": "Only \\(1\\%\\) of patients in both the treatment and placebo groups reported SAEs (2 patients in the Icovamenib group vs 1 patient in the placebo group; all deemed as unrelated to study Tx) There was no treatment or study discontinuation due to TEAE The main TEAEs that disproportionately occurred in the treatment group vs placebo group were diarrhea ( \\(4\\%\\) vs \\(0\\%\\) ), nausea ( \\(4\\%\\) vs \\(1\\%\\) ), and G2 ALT/AST increase ( \\(2\\%\\) vs \\(0\\%\\) ; G1 \\(31\\%\\) vs. \\(25\\%\\) , in line with baseline disease/ natural fluctuation; no G3+; transient/ resolved without Tx interruption; FDA swiftly lifted June '25 clinical hold in Sept '24; see detailed liver AE data in the next slide)",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "fe7afedc93d72eb3",
      "text": "We see the short- term dosing regimen (ie the 12 week induction period tested) as key to reducing long- term safety risk, such as tumorigenesis, but are keen to see more long- term follow up data as well as data from repeat inductions depending on how durable patient results are",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "d53bf06b20c7ff3b",
      "text": "Icovamenib TEAEs Through 26 Weeks Occurring in \\(>5\\%\\) in Any Study Arm (n=267)",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "a36684199a19025f",
      "text": "ParameterArm A icovamenib (N=67)Arm B icovamenib (N=66)Arm C icovamenib (N=67)Combined Arms icovamenib (N=200)Combined Arms placebo (N=67)Diarrhea4 (6)2 (3)1 (1)7 (4)0 (0)Nausea2 (3)3 (5)2 (3)7 (4)1 (1)Hyperglycemia1 (1)4 (6)1 (1)6 (3)3 (4)Headache0 (0)3 (5)1 (1)4 (2)3 (4)ALT increase2 (3)0 (0)2 (3)4 (2)0 (0)AST increase2 (3)0 (0)1 (1)3 (2)0 (0)",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "291318f5cc0e894d",
      "text": "ParameterArm Aicovamenib(N=67)Arm Bicovamenib(N=66)Arm Cicovamenib(N=67)Combined Armsicovamenib(N=200)Combined Armsplacebo(N=67)Any ALT and/or AST elevation, N (%)20 (30)26 (39)20 (30)66 (33)17 (25)Grade 1 elevation, N (%)17 (25)26 (39)19 (28)62 (31)17 (25)Grade 2 elevation, N (%)3 (5)0 (0)1 (2)4 (2)0 (0)Grade 3 elevation, N (%)0 (0)0 (0)0 (0)0 (0)1 (0)Grade 4 elevation, N (%)0 (0)0 (0)0 (0)0 (0)1 (0)Treatment temporarily discontinued due to ALTand/or AST elevation, N (%)0 (0)0 (0)0 (0)0 (0)1 (0)Treatment permanently discontinued due to ALTand/or AST elevation, N (%)0 (0)0 (0)0 (0)0 (0)1 (0)AST and/or ALT elevation resolved withoutinterruption in study treatment, N (%)20 (100)26 (100)20 (100)66 (100)17 (100)",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "0811f3e74a3df7c5",
      "text": "- What pre-clinical data support MOA of menin inhibition for Type 2 Diabetes treatment?",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "8eb88057bb5b323d",
      "text": "- What efficacy and safety data support the further development of Icovamenib in Type 2 Diabetes?",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "64ccc65989e4e8b5",
      "text": "- What is the market opportunity for Icovamenib?",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "1bb1482e1329e356",
      "text": "- How much value does BMEA's earlier pipeline hold?",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "4c25ff8533a2eb86",
      "text": "The T2D landscape has grown and evolved over the last few decades but existing therapies are centered around treating symptoms of T2D by leveraging different indirect mechanisms to decrease blood glucose",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "2b8658143e7287c9",
      "text": "The first line drug is Metformin that decreases glucose output and improves insulin sensitivity to increase glucose uptake- Newer Tx include SGLT2 inhibitors, DPP- 4 inhibitors, TZDs, and GLP- 1 receptor agonists- SGLT2 inhibitors promote renal glucose excretion and has additional benefits beyond glucose control such as protection from chronic kidney disease- DPP- 4 inhibitors increase incretin levels, enhance insulin release, and decrease glucagon secretion- TZDs improve insulin sensitivity to increase glucose uptake- GLP- 1 receptor agonists enhance insulin secretion, suppress glucagon release, and slow gastric emptying",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "6f48386b30eb49b2",
      "text": "Despite the new T2D Tx that have emerged over the last few decades, there still remains a large unmet need for disease- modifying and durably effective Tx",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "ab62cfe25779df11",
      "text": "\\(\\sim 50\\%\\) of T2D pts continue to have uncontrolled blood glucose levels despite the various Tx available. All existing Tx help pts manage symptoms of T2D but there are no disease- modifying Tx that addresses the root causes of disease. Existing Tx have high discontinuation rates and while they show initial efficacy, pts tend to rebound post- discontinuation",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "59b3d54cfe298adb",
      "text": "Khan et al. JAMA 2024 and Alkabbani et al. Diabetes Obes Metab. 2023",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "2affca729c161696",
      "text": "Mean Time to Loss of Glucose Control (HbA1c>7%)",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "36eab14de46d0ac1",
      "text": "Nathan et al. N Engl J Med 2022",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "f703be0720c74ce5",
      "text": "- Icovamenib is well-positioned to be a novel Tx for a specific subset of T2D pts who have beta-cell function that is severely impaired or lost, as in the case for severe insulin-deficient diabetes- T2D pts who are insulin-resistant already produce more insulin than someone without T2D and do not require Tx like icovamenib that work by increasing insulin secretion- Given T2D's enormous pt population, icovamenib's market opportunity is large given that severe insulin-deficient diabetes (SIDD) pts comprise \\(\\sim 18\\%\\) of T2D pts, accounting for \\(\\sim 5.4M\\) initial target pts- Given \\(\\sim 5\\%\\) penetration rate into the SIDD market and \\(15\\%\\) estimated POS, we expect icovamenib to generate adjusted peak sales of \\(\\sim \\$750M\\)",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "a6ef60fcdc337df9",
      "text": "- Icovamenib is one of few T2D drugs in development and the only one that addresses the beta cell loss facet of the disease and targets the underserved SIDD patient population",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "0989a54f35fc9037",
      "text": "- While there are 60+ agents approved for T2D, insulin is the only option approved for SIDD patients, making insulin icovamenib's most relevant competitor currently",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "5c1fb003a092df85",
      "text": "- Besides clinical trials in T2D for updated versions of insulin and long-acting versions of currently approved T2D drugs, most assets in development in this disease space are GLP1/incetin-based Tx such as orforglipron and retratrutide",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "095113bcf9f0afad",
      "text": "- Developing new T2D drugs is difficult given the need for large trial sizes and the high bar for safety given the chronic disease nature of T2D and the availability of approved Tx",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "c3839103130013ad",
      "text": "- What pre-clinical data support MOA of menin inhibition for Type 2 Diabetes treatment?",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "7a3d1afb3a12b9ba",
      "text": "- What efficacy and safety data support the further development of Icovamenib in Type 2 Diabetes?",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "63bbf28f1d22c9f1",
      "text": "- What is the market opportunity for Icovamenib?",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "926064f694c00f7e",
      "text": "- How much value does BMEA's earlier pipeline hold?",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "53894453f123d500",
      "text": "- Icovamenib's MOA positions it to be a potential disease-modifying Tx for T1D pts by replenishing the beta cells previously destroyed by these pts' immune systems through autoimmune attacks",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "285bdd1b0a91163f",
      "text": "- Icovamenib could proliferate sufficient beta cell for T1D, but given the nature of the autoimmune attacks in T1D pts, it could still need to be used in combination with immunosuppressants, in line with treatments in development such as VX-880 which also seek to increase the amount of beta cells of T1D patients, but through a cell Tx transplant, and must be paired with an immunosuppressant",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "90894d94ce1a9483",
      "text": "- Icovamenib would be a good option for pts in the very early stages of their disease journey given the nature of icovamenib's MOA and its need for existing beta cells",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "08e2010bbad6edee",
      "text": "- This may make Icovamenib difficult to position given that patients at the very early stage of their disease are far less likely to opt into a Tx that would require life-long immunosuppression, if needed",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "441c75948444db1d",
      "text": "- It is currently unknown the amount of beta cells necessary for Icovamenib to have therapeutic effect but if its function only required a very small amount, that would enable Icovamenib to reach a greater proportion of patients and later-stage patients who would likely be more amenable to such a Tx",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "672ea0dc8461c6c2",
      "text": "- The T1D Tx landscape only has insulin as its sole Tx option and has not seen any approved therapies since insulin in over 100 years",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "50e35ef57681ffe5",
      "text": "- Insulin only serves as a life-long maintenance therapy that requires constant injections without fundamentally addressing the underlying cause of disease",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "d2dbab62a7ea0025",
      "text": "- T1D affects a large population, with \\(\\sim 2M\\) pts in the U.S. that is continuing to grow year-to-year, making T1D a large commercial opportunity",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "c46a3eeea2213763",
      "text": "- Co will have 52 week data for Icovamenib in T1D in 2H25 but the number of patients with data will be limited due to its previous clinical hold",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "9ece47400aab4fa1",
      "text": "- Co will continue to work with IST to continue dosing T1D patients quickly and do ongoing C-peptide tests",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "21bc9b29c5136944",
      "text": "- Mechanistically, as menin suppresses GLP1 receptor signaling, icova increases GLP1R and insulin expression",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "83455aebe391c915",
      "text": "- Icovamenib has shown an ability to amplify glucose control and weight loss effect in combination with semaglutide in pre-clinical experiments",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "a1b1a4aef84ef6a2",
      "text": "- ZDF treated with a combination of semaglutide and icovamenib had \\(\\sim 60\\%\\) reduction in fasting blood glucose at day 28 vs mice on semaglutide alone",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "aaa27ca749ade88a",
      "text": "- These ZDF mice treated with semaglutide and icovamenib also saw a greater change in body weight vs those on semaglutide alone which was primarily driven by greater fat mass loss rather than lean mass loss",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "586e97742ab32c5e",
      "text": "- The pre-clinical data is further supported by clinical data in the COVALENT-111 study in which N=10 pts with HbA1c uncontrolled despite on background GLP-1R-based therapy saw clinically meaningful 0.8% reduction in HbA1c and additional weight loss after initiating icovamenib of up to 14% at week 26",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "a626404290a0fbcf",
      "text": "- Co expects to start a Ph2 in 2H25",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "ea48bfd9514ad171",
      "text": "- BMF-650 has shown promising pre-clinical PK data in cynomolgus monkeys, superior to orfoglipron, with a 2-3x oral bioavailability vs orfoglipron, and strong on-target potency",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "b91348da40be4e45",
      "text": "- BMF-650 has also shown significant reduction on food intake and significant body weight reduction in obese cynomolgus monkeys through week 4",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "518301d3ba3c24cf",
      "text": "- At low dose tested (10mg/kg) BMF-650 achieved a 12% reduction in average weight while at the high dose tested (30mg/kg), BMF-650 achieved a 15% reduction",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "272f8969b3f2ac90",
      "text": "- Co is currently wrapping up IND enabling studies and expects to enroll the first clinical trial healthy obesity pts in by late 2025, pending IND clearance (IND submission planned for 3Q25), with topline Ph1 SAD/ MAD 4W data in 1H26 (~April/ May)",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "3969d4c02674008f",
      "text": "BMF-650's Effect on Weight Loss in Cynomolgus Monkeys",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "4e47572ebdab680d",
      "text": "- Co reported 26-week topline data for ivanomenib in T2D patients that included an induction period and a maintenance/follow-up period",
      "page": 35,
      "section": null
    },
    {
      "passage_id": "d963efc8c85b871b",
      "text": "ParameterMean (SD) or %Arm AIcovamenib(8 weeks of dosing 100mg QD)(N=45)Arm BIcovamenib(12 weeks of dosing 100 mg QD)(N=37)Arm CIcovamenib(8 weeks of 100 mg QD +4 weeks of 100 BID)(N=33)Combined ArmsIcovamenib(N=115)Combined ArmsPlacebo(N=50)Age (yr)55 (7)56 (6)51 (10)54 (8)55 (7)Duration of T2D Diagnosis (yr)4.3 (1.8)4.7 (1.8)4.2 (2.2)4.4 (1.9)4.3 (2.0)Sex (% Female)3154364042HbA1c (%)8.3 (1.1)8.3 (1.0)8.0 (0.8)8.2 (1.0)8.3 (1.0)Fasting C-peptide (ng/mL)3.4 (1.2)3.9 (1.7)3.7 (1.8)3.7 (1.5)3.5 (1.4)BMI (kg/m2)30.9 (4.7)32.6 (4.5)32.4 (4.9)31.9 (4.7)32.6 (4.1)BMI &lt;30 kg/m2 (%)4924303626BMI ≥30 kg/m2 (%)5173706374",
      "page": 36,
      "section": null
    },
    {
      "passage_id": "a8c19b2e3d37b5da",
      "text": "Number of T2D Medications, n (%)",
      "page": 36,
      "section": null
    },
    {
      "passage_id": "7ad4e7c06164885e",
      "text": "00 (0)0 (0)0 (0)0 (0)O (0)139 (87)23 (62)23 (70)85 (74)41 (82)24 (9)11 (30)7 (21)22 (19)7 (14)32 (4)3 (8)3 (9)8 (7)2 (4)Metformin Monotherapy, n (%)36 (80)18 (49)22 (67)76 (66)38 (76)SGLT2i, n (%)6 (13)13 (35)8 (24)27 (23)8 (16)DPP4i, n (%)3 (7)5 (14)3 (9)11 (10)2 (4)GLP-1 based agent, n (%)3 (7)3 (8)5 (15)11 (10)4 (8)",
      "page": 36,
      "section": null
    },
    {
      "passage_id": "0a6a1159bc566fdf",
      "text": "\"covamenib's recent data has shown an impressive restoration of beta cell function as demonstrated by significant elevations in C- peptide even after the treatment period ended. This data validates the mechanism of action of this menin inhibitor as a disease modifying agent and helps address the poor adherence and persistence commonly seen in type 2 diabetes.\" - Steve Edelman, M.D., Endocrinologist, Professor of Medicine UCSD / VA San Diego",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "5fd14aeb136efe09",
      "text": "\"The icovamenib data looks exciting. After 26 weeks there have been statistically significant and clinically relevant reductions in HbA1c and excellent tolerability in a prespecified insulin- deficient type 2 diabetes cohort. The data presented today help to confirm icovamenib's mechanism of action. A robust increase in insulin secretion, as measured by C- peptide, was demonstrated 3 months after the icovamenib dosing period and this improvement appears to be continuing. We have not previously seen data like this with any antihyperglycemic agent. As more trials are conducted, I believe that inhibition of menin may lead to benefits across all subtypes of diabetes. I applaud Biomega for developing a potential new treatment option that may be disease modifying for patients with diabetes.\" - Ralph DeFronzo, M. D., Endocrinologist, Professor of Medicine UTHSCSA",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "d954cb3f2d106389",
      "text": "\"Great foray into precision medicine. We need to be addressing patients in a much more individualized manner. By addressing insulin- deficient diabetes patients with icovamenib, we have seen post treatment that the beta cell pool is being restored and producing a higher level of insulin, as measured by C- peptide. This indicates a fundamental and potentially lasting impact on the disease and validates the mechanism of action of menin inhibition.\" - Melanie Davies, M.D., Diabetologist, Professor of Diabetes Medicine at the University of Leicester",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "cdf4babbeb7c2cd6",
      "text": "\"covamenib is a very interesting molecule that acts quite differently than anything I have seen before. We are observing glucose controlled and beta cell- specific proliferation and an increase in stimulated C- peptide secretion leading to patient benefits that continued after the icovamenib dosage ended. I am very excited to further explore the many opportunities that the covalent inhibition of menin will provide to patients.\" - Rohit Kulkarni, M.D., Ph.D., Professor of Medicine at Harvard Medical School",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "ef3288f22495d061",
      "text": "\"The C- peptide data which was presented during ATTD is a meaningful update, as we now have insight into why insulin- deficient patients may respond better to icovamenib treatment. The potential to restore endogenous insulin production capacity is an exciting development in the treatment of type 2 diabetes.\" - Jeremy Pettus, M.D., Endocrinologist, Professor of Medicine UCSD",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "656d554f1b5d7b2a",
      "text": "\"We do not have an agent today that addresses one of the root cause of diabetes - beta cell dysfunction - icovamenib would be the first. Patients are achieving lasting benefits without continuous chronic dosing, suggesting that icovamenib may be disease modifying. I am very impressed.\" - Alice Cheng, M.D., Endocrinologist, Associate Professor of Medicine University of Toronto",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "d3e20b206c14f0d9",
      "text": "BMEA was incorporated in 2017 and has its U.S. headquarters in Redwood City, California",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "d8231b1b50f26eaa",
      "text": "- As per BMEA's 2024 10K as of December 31, 2024, Co has \\(\\sim 80\\) employees- During 1H25, Co reduced its workforce and operational expenses",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "64d06e38fd9e320d",
      "text": "BMEA is a biotech company developing covalent small molecules with a focus on inventing and creating molecules in- house by conducting all phases od drug discovery and development (e.g. target selection, small molecule design, pre- clinical studies, clinical trials) themselves",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "4eafb8db9d486d9d",
      "text": "- BMEA has 3 main pipeline products:",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "1d64fe18d4d26fd7",
      "text": "- Icovamenib (menin) in T2D, T1D, and obesity on top of GLP-1 based Tx- BMF-650 (GLP1) in obesity- BMF-500 (FLT3) in AML, to which Co is exploring strategic partnerships",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "71fcfaccf07a27f6",
      "text": "Co is sufficiently funded with cash and cash equivalents, supporting operations into 2H26",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "a9c7e3543dc9633c",
      "text": "- As of June 30, 2025, Co had \\$58.6M of cash, cash equivalents, and short-term investments",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "9e6e173b5e2df160",
      "text": "- Total R&D expenses for the second quarter of 2025 were \\$16.6M, compared to \\$31.8M for the second quarter of 2024. This decrease was primarily due to decreased personnel-related expenses and a reduction in clinical, preclinical, and exploratory programs",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "193601bc3e0d5385",
      "text": "- Total SG&A for the second quarter of 2025 was -16.6M compared to \\$31.8M for the second quarter of 2024.",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "b6704e74774f3c3f",
      "text": "- Co anticipates future quarterly operational expenses to be \\(\\sim 40\\%\\) lower than the most recent quarter, depending on study enrollments and expansion",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "f6463a5e19c5e375",
      "text": "- As of December 31, 2024, BMEA does not have any license or partnership agreements related to its programs but is open to exploring future partnerships",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "700c11b8708c96b1",
      "text": "- As of December 31, 2024, BMEA owns 4 issued U.S. patents and >60 U.S. and outside U.S. pending patent applications",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "23bc046c21281589",
      "text": "- BMEA's patents cover compositions of matter, methods of treatment, and methods of making with respect to their products including icovamenib and BMF-500",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "e541f55621f5d0bd",
      "text": "- BMEA's patents cover their proprietary technologies and products, and are expected to expire between 2039-2042",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "b72e377129490530",
      "text": "- BMEA does not have any of its own manufacturing facilities or personnel",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "a736caaea5b57b2d",
      "text": "- BMEA relies on third parties to manufacture its products for its pre-clinical studies and expects to continue to rely on third parties for products going into clinical trials and for future commercial efforts if its products receive regulatory approval",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "b7665e9ab8fb9707",
      "text": "Michael J.M. Hitchcock, Interim CEO",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "223d579358d54ebd",
      "text": "Dr. Michael J. M. Hitchcock, Ph.D. (Mick) has served as a member of the Company's board since March 2021. Dr. Hitchcock is currently a Past Chair of the University of Nevada, Reno (UNR) Foundation and Adjunct Professor of Microbiology at UNR Medical School, a position in which he has served since July 2016. Dr Hitchcock's career in pharmaceutical research and development initially began with Bristol- Myers Squibb, where he served in several infectious disease research and project planning roles from 1980 through 1993. He joined Gilead Sciences, Inc. in 1993 and during his 27 years with the Company, he held a variety of positions. He also served as Senior Advisor at Gilead from 2009 through November 2019. Dr. Hitchcock holds a Ph.D. in microbiology from the University of Melbourne, Australia and B.Sc. and M.Sc. degrees in biochemistry from the University of Manchester Institute of Science and Technology, England. He also conducted postdoctoral research at Georgetown University and NIH prior to joining industry.",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "f36cab63ea2b6a6f",
      "text": "Ramses Erdtmann, Founder, COO, and President",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "75ad448bc25fbb83",
      "text": "Before co- founding Biomea Fusion in 2017, Ramses co- founded Point Sur Investors, a long- only biotech investment fund dedicated to pioneering therapies. Prior to that, he served as Executive Vice President of Corporate Affairs at Pharmacyclics, where he was instrumental in the company's transformation from a 40- person operation with a \\(\\) 40\\(million market cap in 2009 to a 650 - employee organization valued at\\) \\ \\(21\\) billion at the time of its 2015 merger with AbbVie, Inc. During this period of rapid growth, Ramses led the expansion of core corporate functions, including Finance, Legal, HR, Communications, Investor Relations, Facilities, and IT, supporting the company's scale- up and strategic execution. Earlier in his career, he managed assets for U.S. high- net- worth investors and major European closed- end funds. Ramses began his career at Commerzbank AG in Germany as an investment banker and portfolio manager for international clients. He holds a Diplom Kaufmann degree with distinction in Finance and Banking from the Westfälische Wilhelms- Universität Münster.",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "713a57dba095dc69",
      "text": "Thorsten Kirschberg, Executive VP, Chemistry",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "c6aff5495f977a36",
      "text": "Thorsten received his chemistry training at the universities of Münster/Germany, Osaka/Japan and at Stanford University/USA. He has extensive experience leading teams to discover and develop small molecule drug candidates. He spent more than a decade at Gilead Sciences and contributed to the company's drug portfolio and pipeline. With his team, he synthesized ledipasvir, a component of Harvoni®, to cure HCV infections. He led research to the discovery of GS- 4875, a COT inhibitor in advanced clinical studies for the treatment of IBD. More recently at Terns Pharmaceuticals, his chemistry leadership provided multiple optimized candidates and identified TERN- 501, a selective THR- b agonist for the treatment of NASH.",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "00764faec94351d2",
      "text": "BMEA DCF Analysis ($M)$ M, except per share2023A 2024A 2025E 2026E 2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035ERevenue$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735Operating expenses$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117EBIT($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($114) ($119) ($44) ($55) $49 $110 $236 $306 $444 $583 $588 $594 $601 $609 $618Taxes$0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0EBIT($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($114) ($119) ($44) ($55) $49 $110 $236 $306 $444 $583 $588 $594 $601 $609 $618Plus: Depreciation &amp; amortization$2 $2 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $57 $7 $8 $8 $8 $8 $9 $9 $9 $9Plus: Stock-based compensation$14 $19 $10 $11 $12 $13 $13 $14 $6 $7 $7 $8 $8 $8 $8 $8 $9 $9 $9 $9Minus: Capital expenditures($3) ($0) $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $57 $7 $8 $8 $8 $8 $9 $9 $9 $9Minus: Increase in working capital$2 ($5) $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $57 $7 $8 $8 $8 $8 $9 $9 $9 $9Unlevered Free Cash Flow($112) ($129) ($77) ($81) ($84) ($88) ($92) ($97) ($101) ($106) ($39) $2 $55 $117 $194 $250 $358 $469 $473 $478 $484 $490 $497PV of Cash Flow($112) ($129) ($77) ($81) ($84) ($88) ($92) ($97) ($101) ($106) ($39) $2 $55 $117 $194 $250 $358 $469 $473 $478 $484 $490 $497NPV of Cash Flows 2026E - 2045E$206 12%Platform/ pipeline/ partnership Value$100Enterprise Value (EV)$306Plus: Net Cash/equivalents (End 2025, pro forma)$21Equity Value$327# Of Shares in M Outstanding at the End of 202564.2DCF Value per Share$5Source: Company reports and Jefferies research",
      "page": 42,
      "section": null
    },
    {
      "passage_id": "4ccb74075aaec254",
      "text": "Biomea FusionStatement of OperationsFY Ends December 31(In M's except per share amounts)Revenues2023A2024AQ1 2025AQ2 2025EQ3 2025EQ4 2025E2025E2026E2027E2028E2029E2030EIcovamenib Revenues in T2D\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(0.00\\)\\(0.0\\)\\(0.0\\)\\(0,0\\)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(.0.0\\)\\(0.0\\)Total Revenues\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(0.00\\)\\(0.0\\)\\(0.0\\)\\(0,0\\)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(.0.0\\)\\(0.0\\)ExpensesCost of Goods Sold\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(0.00\\)\\(0.0\\)\\(0.0\\)\\(0,0\\)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(.0.0\\)\\(0.0\\)Gross profit\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(0.00\\)\\(0.0\\)\\(0.0\\)\\(0,0\\)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(.0.0\\)\\(0.0\\)Operating expensesTotal research and development\\(102.5\\)\\(118.1\\)\\(22.9\\)\\(16.6\\)\\(14.9\\)\\(13.4\\)\\(67.8\\)\\(71.2\\)\\(74.7\\)\\(78.5\\)\\(82.4\\)\\(86.5\\)Total general and administrative\\(23.6\\)\\(26.0\\)\\(6.8\\)\\(4.7\\)\\(4.2\\)\\(3.8\\)\\(19.6\\)\\(20.2\\)\\(20.8\\)\\(21.4\\)\\(22.0\\)\\(22.7\\)Milestone and Royalties Payments\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(0.00\\)\\(0.0\\)\\(0.0\\)\\(0,0\\)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(.0.0\\)\\(0.0\\)Other expense (income)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(0.00\\)\\(0.0\\)\\(0.0\\)\\(0,0\\)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(.0.0\\)\\(0.0\\)Total OPEX\\(126.1\\)\\(114.1\\)\\(29.7\\)\\(21.3\\)\\(19.1\\)\\(17.2\\)\\(87.4\\)\\(91.3\\)\\(95.5\\)\\(99.9\\)\\(104.4\\)\\(109.2\\)OPERATING INCOME(\\(126.1\\))(\\(114.1\\))(\\(29.7\\))(\\(21.3\\))(\\(19.1\\))(\\(17.2\\))(\\(87.4\\))(\\(91.3\\))(\\(95.5\\))(\\(99.9\\))(\\(104.4\\))(\\(109.2\\))Non-operating expensesInterest income (expenses), net\\(8.9\\)\\(5.6\\)\\(0.5\\)\\(0.5\\)\\(0.0\\)\\(0.0\\)\\(0,0\\)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(.0.0\\)\\(0.0\\)Other Income (expenses), net\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(0.00\\)\\(0.0\\)\\(0.0\\)\\(0,0\\)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(.0.0\\)\\(0.0\\)Income (Loss) before income tax expense(\\(117.3\\))(\\(138.4\\))(\\(29.3\\))(\\(20.7\\))(\\(19.1\\))(\\(17.2\\))(\\(86.4\\))(\\(91.3\\))(\\(95.5\\))(\\(99.9\\))(\\(104.4\\))(\\(109.2\\))Income tax expense (benefit)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(0.00\\)\\(0.0\\)\\(0.0\\)\\(0,0\\)\\(0.0\\)\\(0.0\\)\\(0.0\\)\\(.0.0\\)\\(0.0\\)Net Income (GAAP)(\\(117.3\\))(\\(138.4\\))(\\(29.3\\))(\\(20.7\\))(\\(19.1\\))(\\(17.2\\))(\\(86.4\\))(\\(91.3\\))(\\(95.5\\))(\\(99.9\\))(\\(104.4\\))(\\(109.2\\))EPS Basic (GAAP)(\\(3.44\\))(\\(3.83\\))(\\(0.80\\))(\\(0.50.1\\))(\\(0.32\\))(\\(0.28\\))(\\(1.74\\))(\\(0.91\\))(\\(0.96\\))(\\(0.63\\))(\\(0.66\\))(\\(0.46\\))EPS Diluted (GAAP)(\\(3.44\\))(\\(3.83\\))(\\(0.80\\))(\\(0.50.1\\))(\\(0.32\\))(\\(0.28\\))(\\(1.71\\))(\\(0.88\\))(\\(0.92\\))(\\(0.61\\))(\\(0.64\\))(\\(0.45\\))Net Income (Non-GAAP)(\\(103.1\\))(\\(119.3\\))(\\(26.1\\))(\\(18.2\\))(\\(16.8\\))(\\(15.1\\))(\\(76.2\\))(\\(80.7\\))(\\(84.4\\))(\\(88.3\\))(\\(92.3\\))(\\(96.5\\))EPS Basic (Non-GAAP)(\\(3.0\\))(\\(3.3\\))(\\(0.7\\))(\\(0.4\\))(\\(0.3\\))(\\(0.2\\))(\\(1.5\\))(\\(0.8\\))(\\(0.8\\))(\\(0.6\\))(\\(0.6\\))(\\(0.4\\))EPS Diluted (Non-GAAP)(\\(3.0\\))(\\(3.3\\))(\\(0.7\\))(\\(0.4\\))(\\(0.3\\))(\\(0.2\\))(\\(1.5\\))(\\(0.8\\))(\\(0.8\\))(\\(0.5\\))(\\(0.6\\))(\\(0.4\\))Total stock-based compensation expense\\(14.1\\)\\(19.1\\)\\(3.2\\)\\(2.6\\)\\(2.3\\)\\(2.1\\)\\(10.1\\)\\(10.6\\)\\(11.1\\)\\(11.6\\)\\(12.1\\)\\(12.7\\)R&D stock-based compensation expense\\(6.9\\)\\(9.8\\)\\(1.9\\)\\(1.6\\)\\(1.4\\)\\(1.3\\)\\(6.2\\)\\(6.5\\)\\(6.8\\)\\(7.1\\)\\(7.5\\)\\(7.9\\)G&A stock-based compensation expense\\(7.2\\)\\(9.3\\)\\(1.2\\)\\(1.0\\)\\(0.9\\)\\(0.8\\)\\(4.0\\)\\(4.1\\)\\(4.2\\)\\(4.3\\)\\(4.5\\)\\(4.6\\)Shares Outstanding (Basic)\\(34.1\\)\\(36.1\\)\\(36.6\\)\\(40.6\\)\\(60.6\\)\\(60.6\\)\\(49.6\\)\\(99.9\\)\\(99.9\\)\\(158.9\\)\\(158.9\\)\\(237.5\\)Shares Outstanding (Diluted)\\(34.1\\)\\(36.1\\)\\(36.6\\)\\(40.6\\)\\(60.6\\)\\(60.6\\)\\(49.6\\)\\(103.5\\)\\(103.5\\)\\(162.5\\)\\(162.5\\)\\(241.1\\)",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "6c857bc0d4be0c6f",
      "text": "Source: Company reports and Jefferies research",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "52d49f3c37dfcfc3",
      "text": "Biomea FusionBalance Sheet(in M&#36; s)FY Ends December 31ASSETS2023A2024A2025E2026E2027E2028E2029E2030ECurrent Assets:Cash and cash equivalents$176.9$58.3$20.6$148.7$64.3$276.0$183.7$487.1Marketable securities and investment$0.0$0.0$0.0$0.0$0.0$0.0$0.1Accounts receivable$0.0$0.0$0.0$0.0$0.0$0.0$0.2Inventory$0.0$0.0$0.0$0.0$0.0$0.0$0.3Prepaid expenses and other current assets$2.3$10.1$10.1$10.1$10.1$10.1$10.1Other current Assets$0.0$0.0$0.0$0.0$0.0$0.0$0.4Total Current Assets$179.2$68.3$30.6$158.7$74.3$286.0$193.7$497.2Property and equipment, net$5.2$3.8$3.8$3.8$3.8$3.8$3.8Marketable securities and investment, non-current$0.0$0.0$0.0$0.0$0.0$0.0$0.5Accounts receivable, non-current$0.0$0.0$0.0$0.0$0.0$0.0$0.6Intangible assets$0.0$0.0$0.0$0.0$0.0$0.0$0.7Goodwill$0.0$0.0$0.0$0.0$0.0$0.0$0.8Right of Use Assets$9.7$6.9$6.9$6.9$6.9$6.9$6.9Restricted cash$0.4$0.4$0.4$0.4$0.4$0.4$0.9Other non-current assets$5.5$0.6$0.6$0.6$0.6$0.6$0.6TOTAL ASSETS$199.9$79.9$42.2$170.3$85.9$297.6$205.3$508.8LIABILITIES &amp; STOCKHOLDERS EQUITYCurrent Liabilities",
      "page": 44,
      "section": null
    },
    {
      "passage_id": "eb0403b3198e4a28",
      "text": "Biomea FusionCash Flow Statement(In M&#x27;s $)FY Ends December 31CASH FLOWS FROM OPERATING ACTIVITIESNet income (loss)-&#x27;117.3-&#x27;138.4-&#x27;86.4-&#x27;91.3-&#x27;95.5-&#x27;99.9-&#x27;104.4-&#x27;109.2Depreciation and amortization&#x27;1.5&#x27;1.7&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.0&#x27;0Non-cash operating lease expense&#x27;2.7&#x27;2.8&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.0&#x27;0Stock-based compensation expense&#x27;14.1&#x27;19.1&#x27;10.1&#x27;10.6&#x27;11.1&#x27;11.6&#x27;12.1&#x27;12.7Net amortization of premiums and accretion of discounts on investments&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.0&#x27;0&#x27;0&#x27;0Other non cash adjustments&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.0&#x27;0&#x27;0&#x27;0Change in operating assets &amp;amp; liabilitiesAccounts receivable&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.0&#x27;0&#x27;0&#x27;0Prepaid expenses and other assets&#x27;2.5-&#x27;7.7&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0&#x27;0Other assets-&#x27;2.4&#x27;4.9&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0&#x27;0Accounts payable&#x27;2.6&#x27;6.1&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0&#x27;0Accrued expenses and other liabilities&#x27;1.9-&#x27;6.9&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0&#x27;0Operating lease liabilities-&#x27;2.2-&#x27;1.5&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0&#x27;0Net cash provided by (used in) operating activities&#x27;2.3-&#x27;5.1&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0&#x27;0Net Cash from Operations-&#x27;96.6-&#x27;119.9-&#x27;76.2-&#x27;80.7-&#x27;84.4-&#x27;88.3-&#x27;92.3-&#x27;96.5CASH FLOWS FROM INVESTING ACTIVITIESPurchases of PPE-&#x27;3.4-&#x27;0.4&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0&#x27;0Purchase of investments&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.00.00.0&#x27;0Proceeds from maturity of short-term securities&#x27;1.2&#x27;0.0&#x27;0.0&#x27;0.00.00.0&#x27;0&#x27;0Other investment activities&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.00.00.0&#x27;0Net Cash from Investing-&#x27;2.2-&#x27;0.4&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0&#x27;0CASH FLOWS FROM FINANCING ACTIVITIESProceeds from issuance of common stock, net of issuance costs&#x27;161.8&#x27;0.0&#x27;38.5&#x27;200.0&#x27;0.0&#x27;300.0&#x27;0.0&#x27;400.0Proceeds from initial public offering, net of issuance costs&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.00.00.0&#x27;0Proceeds from exercise of stock options, warrants, and purchases under employee stock purchase plan&#x27;2.0&#x27;1.7&#x27;0.0&#x27;8.9&#x27;0.0&#x27;0.00.0&#x27;0Payment from Paycheck Protection Program loan&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.00.00.0&#x27;0Net Cash from Financing&#x27;163.8&#x27;1.7&#x27;38.5&#x27;208.9&#x27;0.0&#x27;300.0&#x27;0.0&#x27;400.0Net Increase in Net Cash&#x27;65.0-&#x27;118.6-&#x27;37.7&#x27;128.1-&#x27;84.4&#x27;211.7-&#x27;92.3&#x27;303.5Exchange Rate Changes&#x27;0.0&#x27;0.0&#x27;0.00.0&#x27;0.00.00.0&#x27;0Net Cash at beginning of period&#x27;112.3&#x27;177.2&#x27;58.6&#x27;20.9&#x27;149.1&#x27;64.6&#x27;276.4&#x27;184.0Net Cash/ Securities, End of Period&#x27;177.2&#x27;58.6&#x27;20.9&#x27;149.1&#x27;64.6&#x27;276.4&#x27;184.0&#x27;487.5",
      "page": 45,
      "section": null
    },
    {
      "passage_id": "9c50fbe2a0e6034c",
      "text": "Source: Company reports and Jefferies estimates",
      "page": 45,
      "section": null
    },
    {
      "passage_id": "86d2059984d4b972",
      "text": "BiomeaBiomea Fusion is a clinical- stage diabetes and obesity medicines company focused on the development of its oral small molecules, including its pipeline assets icovamenib and BMF- 650.",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "b1f4b21317923ee1",
      "text": "Our PT is DCF- based. Key risks: clinical, regulatory and commercial.",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "e0ecda8262cfd355",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "70586ce2d3e879f1",
      "text": "August 27, 2025 18:48 P.M. August 28, 2025 5:00 A.M.",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "bc5089a056941524",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Biomea Fusion within the next three months. Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Biomea Fusion. Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Biomea Fusion or one of its affiliates within the past twelve months. Within the past twelve months, Biomea Fusion has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "b9824447144468b5",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period.",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "3683f98e1dbddc01",
      "text": "The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10 is 20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10, the expected total return (price appreciation plus yield) is plus or minus 20% within a 12-month period. For Underperform rated securities with an average security price consistently below\\) 10, the expected total return (price appreciation plus yield) is minus 20% or less within a 12-month period.",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "30dc8bb66fed12ea",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "931c986905165821",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "40f2859edbdf9b42",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "a3bc141537c2bd72",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "5feee9c1377a2905",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "fc28d0248b042964",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "c678188d439f5be4",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "586a1932224dca20",
      "text": "**Notes**: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company,made a change to a rating or price target of a company or discontinued coverage of a company.",
      "page": 48,
      "section": null
    },
    {
      "passage_id": "85bdf5c081be222a",
      "text": "I: Initiating Coverage",
      "page": 48,
      "section": null
    },
    {
      "passage_id": "9df6ae094ca0acd5",
      "text": "Distribution of RatingsIB Serv./Past12 Mos.JIL Mkt Serv./Past12 Mos.CountPercentCountPercentCountBUY211260.69%36717.38%1175.54%HOLD121134.80%1058.67%221.82%UNDERPERFORM1574.51%31.91%31.91%",
      "page": 48,
      "section": null
    },
    {
      "passage_id": "ae9df1fa6ab08eb6",
      "text": "Jefferies does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "fa90638db23e733a",
      "text": "Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies: United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "fefa61666ebc51b0",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "029b1a0093bd3f5e",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "9c5290289e454c48",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "78fe7dca119311a6",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "86ea78a339e7e560",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "8f7fb54866214cc6",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "c9bdc51deb0a6ddb",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "f2ca2a79604a43ce",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "8d3632ce4b818ac7",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a permitted client as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and risks of a security or securities only, and is not in any way meant to be tailored to the needs and circumstances of any recipient. The information contained herein is not, and under no circumstances is to be construed as, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators, if applicable, and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon this research report, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence.",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "3e1a23908353fb31",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker-dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser, and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "81c935fda5fae7ba",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "2e33d15b48a6a6bf",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "b74bdff41bd6705c",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "0e59c549a540c59f",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third-party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third-party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third-party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 51,
      "section": null
    },
    {
      "passage_id": "dc830db3f3c9ee2c",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 51,
      "section": null
    },
    {
      "passage_id": "0b49fa7ca619467f",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES.",
      "page": 51,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "2b59e4754daf87a5",
      "name": "Adjunct Professor",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "aaec43cb162e149c",
      "name": "Administration Route",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "433e14e325eb445a",
      "name": "Alice Cheng",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ae6f763e328e412",
      "name": "Any ALT",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e0f66cbc972de57a",
      "name": "Any Study",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d2e9a8b91fead3c3",
      "name": "Associate Professor",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b7c729c0e2366001",
      "name": "Balance Sheet",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f7ead7c7bfac812b",
      "name": "Baseline During",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "42dd8aa3ef6fa834",
      "name": "Beta Cell",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9fc79b5e1d77ac32",
      "name": "Biomea\n\nBiomeaBiomea",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cebb2d47a9ce05d6",
      "name": "Biomea\n\nOur",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f59ceba0cdc452f0",
      "name": "Biomea Fusion",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d8886a557d13600d",
      "name": "Biotechnology\n\nBiomea",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4921a4e31f90c434",
      "name": "Blood Glucose",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dc62425edd02dcb2",
      "name": "Cash Flow",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cafa41aae33c1211",
      "name": "Cash Flows",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9d830a0ff19dc9ee",
      "name": "Catalysts\n\nIcovamenib",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9ea2db3f1b1df8d7",
      "name": "Chemistry\n\nThorsten",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "1bc82bad600a37de",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 3,
        "axes": null,
        "series": [],
        "figure_id": "eb0ac9477709486f",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025",
              "+12 mo."
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 20
            }
          }
        },
        "series": [
          {
            "name": "Historical Data",
            "unit": null,
            "values": [
              {
                "x": "2024-01",
                "y": 17
              },
              {
                "x": "2024-02",
                "y": 10.5
              },
              {
                "x": "2024-03",
                "y": 19
              },
              {
                "x": "2024-04",
                "y": 14
              },
              {
                "x": "2024-05",
                "y": 16
              },
              {
                "x": "2024-06",
                "y": 14
              },
              {
                "x": "2024-07",
                "y": 11
              },
              {
                "x": "2024-08",
                "y": 12
              },
              {
                "x": "2024-09",
                "y": 10
              },
              {
                "x": "2024-10",
                "y": 5
              },
              {
                "x": "2024-11",
                "y": 6
              },
              {
                "x": "2024-12",
                "y": 12
              },
              {
                "x": "2025-01",
                "y": 8
              },
              {
                "x": "2025-02",
                "y": 6
              },
              {
                "x": "2025-03",
                "y": 4
              },
              {
                "x": "2025-04",
                "y": 3
              },
              {
                "x": "2025-05",
                "y": 2
              },
              {
                "x": "2025-06",
                "y": 1.5
              },
              {
                "x": "2025-07",
                "y": 2
              },
              {
                "x": "2025-08",
                "y": 2.5
              },
              {
                "x": "2025-09",
                "y": 2
              },
              {
                "x": "2025-10",
                "y": 2.5
              },
              {
                "x": "2025-11",
                "y": 2
              }
            ]
          },
          {
            "name": "Forecast - Upside",
            "unit": null,
            "values": [
              {
                "x": "2025-11",
                "y": 2
              },
              {
                "x": "+12 mo.",
                "y": 18.0
              }
            ]
          },
          {
            "name": "Forecast - Base",
            "unit": null,
            "values": [
              {
                "x": "2025-11",
                "y": 2
              },
              {
                "x": "+12 mo.",
                "y": 5.0
              }
            ]
          },
          {
            "name": "Forecast - Downside",
            "unit": null,
            "values": [
              {
                "x": "2025-11",
                "y": 2
              },
              {
                "x": "+12 mo.",
                "y": 0.5
              }
            ]
          }
        ],
        "figure_id": "b77111313f46e837",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "other",
        "title": "Menin regulates beta-cell quiescence (cell cycle arrest)",
        "page": 14,
        "axes": null,
        "series": [
          {
            "name": "Menin",
            "unit": null,
            "values": []
          },
          {
            "name": "Transcription Factors including JunD",
            "unit": null,
            "values": []
          },
          {
            "name": "Histone Regulators",
            "unit": null,
            "values": []
          },
          {
            "name": "Menin Target Genes",
            "unit": null,
            "values": []
          },
          {
            "name": "CDKIs",
            "unit": null,
            "values": []
          },
          {
            "name": "CDKs",
            "unit": null,
            "values": []
          },
          {
            "name": "CDK inhibition results in beta-cell quiescence",
            "unit": null,
            "values": []
          }
        ],
        "figure_id": "c4abe34c1d30fbb2",
        "provenance": {
          "page": 14
        }
      },
      {
        "type": "other",
        "title": "Menin inhibition by BMF-219 allows for beta-cell regeneration (cell cycle entry) and glucose homeostasis",
        "page": 14,
        "axes": null,
        "series": [
          {
            "name": "Menin",
            "unit": null,
            "values": []
          },
          {
            "name": "BMF-219",
            "unit": null,
            "values": []
          },
          {
            "name": "Transcription Factors Including JunD",
            "unit": null,
            "values": []
          },
          {
            "name": "Histone Regulators",
            "unit": null,
            "values": []
          },
          {
            "name": "CDKIs",
            "unit": null,
            "values": []
          },
          {
            "name": "Menin Target Genes",
            "unit": null,
            "values": []
          },
          {
            "name": "CDKs",
            "unit": null,
            "values": []
          },
          {
            "name": "CDKI downregulating allows for beta-cell growth",
            "unit": null,
            "values": []
          },
          {
            "name": "Nucleus",
            "unit": null,
            "values": []
          }
        ],
        "figure_id": "223c28c3ab106b6c",
        "provenance": {
          "page": 14
        }
      },
      {
        "type": "other",
        "title": "Mechanism of BMF-219 Action",
        "page": 15,
        "axes": {},
        "series": [
          {
            "name": "BMF-219",
            "unit": null,
            "values": [
              "covalently inhibits menin"
            ]
          },
          {
            "name": "menin",
            "unit": null,
            "values": [
              "inhibition leads to beta-cell proliferation"
            ]
          },
          {
            "name": "beta cells",
            "unit": null,
            "values": [
              "proliferate into beta cell pool"
            ]
          },
          {
            "name": "beta cell pool",
            "unit": null,
            "values": [
              "leads to more insulin released"
            ]
          },
          {
            "name": "more insulin released",
            "unit": null,
            "values": [
              "leads to lower glucose level"
            ]
          }
        ],
        "figure_id": "06e67415cc9e329c",
        "provenance": {
          "page": 15
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 16,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Day 1",
              "Day 21",
              "Day 29"
            ]
          },
          "y": {
            "unit": "mg/dL",
            "range": {
              "min": 0,
              "max": 800
            }
          }
        },
        "series": [
          {
            "name": "Vehicle 0mg/kg",
            "unit": "mg/dL",
            "values": [
              470,
              500,
              560
            ]
          },
          {
            "name": "BMF-219 40 mg/kg PO",
            "unit": "mg/dL",
            "values": [
              440,
              370,
              310
            ]
          },
          {
            "name": "BMF-219 170mg/kg PO",
            "unit": "mg/dL",
            "values": [
              420,
              340,
              450
            ]
          },
          {
            "name": "Liraglu",
            "unit": "mg/dL",
            "values": [
              420,
              360,
              500
            ]
          }
        ],
        "figure_id": "ec3fdcf03e7bf7a5",
        "provenance": {
          "page": 16
        }
      },
      {
        "type": "line",
        "title": "2-hr post-OGTT glucose",
        "page": 16,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "0",
              "15",
              "30",
              "60",
              "90",
              "120"
            ]
          },
          "y": {
            "unit": "mg/dL",
            "range": {
              "min": 300,
              "max": 900
            }
          }
        },
        "series": [
          {
            "name": "Series 1 (Black circles)",
            "unit": "mg/dL",
            "values": [
              580,
              655,
              690,
              765,
              700,
              650
            ]
          },
          {
            "name": "Series 2 (Blue squares)",
            "unit": "mg/dL",
            "values": [
              390,
              480,
              450,
              460,
              485,
              390
            ]
          },
          {
            "name": "Series 3 (Green triangles)",
            "unit": "mg/dL",
            "values": [
              440,
              500,
              530,
              575,
              515,
              470
            ]
          },
          {
            "name": "Series 4 (Orange circles)",
            "unit": "mg/dL",
            "values": [
              445,
              410,
              405,
              550,
              500,
              475
            ]
          }
        ],
        "figure_id": "0a82418202152d85",
        "provenance": {
          "page": 16
        }
      },
      {
        "type": "bar",
        "title": "Blood Glucose, Insulin, and C-peptide (4hr fasting)",
        "page": 17,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "on Day 17",
              "on Day 31\nTwo weeks after last dose"
            ]
          },
          "y": {
            "unit": null,
            "range": null
          }
        },
        "series": [
          {
            "name": "Blood Glucose (4hr fasting) - Vehicle",
            "unit": "mg/dL",
            "values": [
              310,
              480
            ]
          },
          {
            "name": "Blood Glucose (4hr fasting) - Pioglitazone (30 mg/kg)",
            "unit": "mg/dL",
            "values": [
              140,
              390
            ]
          },
          {
            "name": "Blood Glucose (4hr fasting) - BMF-219 (175mg/kg)",
            "unit": "mg/dL",
            "values": [
              180,
              250
            ]
          },
          {
            "name": "Insulin (4hr fasting) - Vehicle",
            "unit": "ng/mL",
            "values": [
              4.5,
              2.5
            ]
          },
          {
            "name": "Insulin (4hr fasting) - Pioglitazone (30 mg/kg)",
            "unit": "ng/mL",
            "values": [
              1.5,
              8.5
            ]
          },
          {
            "name": "Insulin (4hr fasting) - BMF-219 (175mg/kg)",
            "unit": "ng/mL",
            "values": [
              2.5,
              5.5
            ]
          },
          {
            "name": "C-peptide (4hr fasting) - Vehicle",
            "unit": "pM",
            "values": [
              3500,
              1200
            ]
          },
          {
            "name": "C-peptide (4hr fasting) - Pioglitazone (30 mg/kg)",
            "unit": "pM",
            "values": [
              800,
              4500
            ]
          },
          {
            "name": "C-peptide (4hr fasting) - BMF-219 (175mg/kg)",
            "unit": "pM",
            "values": [
              1500,
              4300
            ]
          }
        ],
        "figure_id": "9fa0c28361cc270d",
        "provenance": {
          "page": 17
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 18,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Vehicle",
              "Pioglitazone (30 mg/kg)",
              "BMF-219 (175mg/kg)"
            ]
          },
          "y": {
            "unit": "Pct. Change",
            "range": {
              "min": -0.4,
              "max": 0.1
            }
          }
        },
        "series": [
          {
            "name": "Vehicle",
            "unit": "%",
            "values": [
              -0.33
            ]
          },
          {
            "name": "Pioglitazone (30 mg/kg)",
            "unit": "%",
            "values": [
              -0.28
            ]
          },
          {
            "name": "BMF-219 (175mg/kg)",
            "unit": "%",
            "values": [
              0.02
            ]
          }
        ],
        "figure_id": "0a6e3c23fc186e2b",
        "provenance": {
          "page": 18
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 18,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Vehicle",
              "BMF-219 (175mg/kg)"
            ]
          },
          "y": {
            "unit": "HOMA-B",
            "range": {
              "min": 0,
              "max": 400
            }
          }
        },
        "series": [
          {
            "name": "Vehicle",
            "unit": "HOMA-B",
            "values": [
              60
            ]
          },
          {
            "name": "BMF-219 (175mg/kg)",
            "unit": "HOMA-B",
            "values": [
              290
            ]
          }
        ],
        "figure_id": "873fc6ac9cc52633",
        "provenance": {
          "page": 18
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 20,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Wk 0",
              "Wk 4",
              "Wk 8",
              "Wk 12",
              "Wk 16",
              "Wk 22",
              "Wk 26"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -1.0,
              "max": 0.4
            }
          }
        },
        "series": [
          {
            "name": "Placebo",
            "unit": "%",
            "values": [
              0.0,
              0.2,
              -0.01,
              0.08,
              0.28,
              0.2,
              0.15
            ]
          },
          {
            "name": "icovamenib",
            "unit": "%",
            "values": [
              0.0,
              -0.15,
              -0.35,
              -0.4,
              -0.6,
              -0.62,
              -0.8
            ]
          }
        ],
        "figure_id": "8e287744a80ab237",
        "provenance": {
          "page": 20
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 20,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Wk 0",
              "Wk 4",
              "Wk 8",
              "Wk 12",
              "Wk 16",
              "Wk 22",
              "Wk 26"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -1.4,
              "max": 0.4
            }
          }
        },
        "series": [
          {
            "name": "placebo",
            "unit": "%",
            "values": [
              0,
              0.21,
              0,
              0.08,
              0.28,
              0.21,
              0.15
            ]
          },
          {
            "name": "icovamenib",
            "unit": "%",
            "values": [
              0,
              -0.45,
              -1.0,
              -0.6,
              -0.95,
              -0.88,
              -1.3
            ]
          }
        ],
        "figure_id": "c18e4ccc2e41726a",
        "provenance": {
          "page": 20
        }
      },
      {
        "type": "line",
        "title": "Placebo-Adjusted C-Peptide Change from Baseline",
        "page": 22,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "0",
              "2",
              "4",
              "6",
              "8",
              "10",
              "12",
              "14",
              "16",
              "18",
              "20",
              "22",
              "24",
              "26"
            ]
          },
          "y": {
            "unit": "Fold-Change in C-Peptide",
            "range": {
              "min": 0.6,
              "max": 1.8
            }
          }
        },
        "series": [
          {
            "name": "SIDD Active (N=23)",
            "unit": "Fold-Change in C-Peptide",
            "values": [
              1.0,
              null,
              null,
              null,
              1.3,
              null,
              1.25,
              null,
              1.2,
              null,
              null,
              1.45,
              null,
              1.35
            ]
          },
          {
            "name": "MARD Active (N=22)",
            "unit": "Fold-Change in C-Peptide",
            "values": [
              1.0,
              null,
              null,
              null,
              1.1,
              null,
              1.3,
              null,
              1.15,
              null,
              null,
              1.25,
              null,
              1.35
            ]
          },
          {
            "name": "MOD Active (N=63)",
            "unit": "Fold-Change in C-Peptide",
            "values": [
              1.0,
              null,
              null,
              null,
              1.05,
              null,
              1.15,
              null,
              1.1,
              null,
              null,
              1.0,
              null,
              1.0
            ]
          },
          {
            "name": "SIRD Active (N=6)",
            "unit": "Fold-Change in C-Peptide",
            "values": [
              1.0,
              null,
              null,
              null,
              1.25,
              null,
              1.15,
              null,
              1.0,
              null,
              null,
              1.0,
              null,
              0.9
            ]
          }
        ],
        "figure_id": "54185a891223b987",
        "provenance": {
          "page": 22
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 23,
        "axes": {
          "x": {
            "type": "value",
            "labels": "Week"
          },
          "y": {
            "unit": "Fold Change in C-Peptide",
            "range": {
              "min": 0.5,
              "max": 2.0
            }
          }
        },
        "series": [
          {
            "name": "Icovamenib Treatment",
            "unit": "Fold Change in C-Peptide",
            "values": [
              {
                "x": 0,
                "y": 1.0
              },
              {
                "x": 8,
                "y": 1.08
              },
              {
                "x": 12,
                "y": 1.25
              },
              {
                "x": 16,
                "y": 1.28
              },
              {
                "x": 22,
                "y": 1.53
              },
              {
                "x": 26,
                "y": 1.52
              }
            ]
          },
          {
            "name": "Control",
            "unit": "Fold Change in C-Peptide",
            "values": [
              {
                "x": 0,
                "y": 1.0
              },
              {
                "x": 8,
                "y": 0.75
              },
              {
                "x": 12,
                "y": 0.95
              },
              {
                "x": 16,
                "y": 1.05
              },
              {
                "x": 22,
                "y": 1.0
              },
              {
                "x": 26,
                "y": 1.07
              }
            ]
          }
        ],
        "figure_id": "c116aff2fbfd4c83",
        "provenance": {
          "page": 23
        }
      },
      {
        "type": "other",
        "title": "Mechanisms of Action of Antidiabetic Drugs",
        "page": 27,
        "axes": {},
        "series": [
          {
            "name": "Muscle",
            "unit": null,
            "values": [
              {
                "drug": "Metformin",
                "effect": "↑ Glucose uptake"
              },
              {
                "drug": "TZDs",
                "effect": "↑ Glucose uptake"
              }
            ]
          },
          {
            "name": "Pancreas",
            "unit": null,
            "values": [
              {
                "drug": "Meglitinides, Sulphonylureas",
                "effect": "↑ Insulin release"
              },
              {
                "drug": "DPP-4i, GLP-1RA",
                "effect": "↓ Glucagon secretion, ↑ Insulin secretion"
              }
            ]
          },
          {
            "name": "Liver",
            "unit": null,
            "values": [
              {
                "drug": "TZDs",
                "effect": "↑ Insulin sensitivity"
              },
              {
                "drug": "Metformin",
                "effect": "↓ Gluconeogenesis"
              }
            ]
          },
          {
            "name": "Kidney",
            "unit": null,
            "values": [
              {
                "drug": "SGLT-2i",
                "effect": "↑ Renal glucose excretion"
              }
            ]
          },
          {
            "name": "Adipose Tissue",
            "unit": null,
            "values": [
              {
                "drug": "TZDs",
                "effect": "↑ Glucose uptake"
              }
            ]
          },
          {
            "name": "Intestine",
            "unit": null,
            "values": [
              {
                "drug": "GLP-1RA",
                "effect": "↓ Gastric emptying"
              },
              {
                "drug": "DPP-4i",
                "effect": "↑ GLP-1"
              },
              {
                "drug": "Metformin",
                "effect": "↑ GLP-1, ↓ Glucose absorption"
              }
            ]
          }
        ],
        "figure_id": "72ef61d8aa2c4b2e",
        "provenance": {
          "page": 27
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 28,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "GLP-1 RAs (12 months)",
              "SGLT2i (18 months)",
              "DPP-4i (18 months)"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Percentage",
            "unit": "%",
            "values": [
              75,
              69,
              74
            ]
          }
        ],
        "figure_id": "efeaa74643a5788a",
        "provenance": {
          "page": 28
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 28,
        "axes": {
          "x": {
            "type": "value",
            "labels": null,
            "unit": "years",
            "range": {
              "min": 0.0,
              "max": 4.0
            }
          },
          "y": {
            "type": "category",
            "labels": [
              "Sitagliptin",
              "Glimepiride",
              "Glargine",
              "Liraglutide"
            ]
          }
        },
        "series": [
          {
            "name": "Sitagliptin",
            "unit": "days",
            "values": [
              697
            ]
          },
          {
            "name": "Glimepiride",
            "unit": "days",
            "values": [
              809
            ]
          },
          {
            "name": "Glargine",
            "unit": "days",
            "values": [
              861
            ]
          },
          {
            "name": "Liraglutide",
            "unit": "days",
            "values": [
              882
            ]
          }
        ],
        "figure_id": "461b0d1547702a4d",
        "provenance": {
          "page": 28
        }
      },
      {
        "type": "bar",
        "title": "Body weight reduction",
        "page": 34,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "week 1",
              "week 2",
              "week 3",
              "week 4"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -20,
              "max": 5
            }
          }
        },
        "series": [
          {
            "name": "Vehicle",
            "unit": "%",
            "values": [
              -2.3,
              -2.7,
              -2.8,
              -3.4
            ]
          },
          {
            "name": "BMF-650, 10mg/kg",
            "unit": "%",
            "values": [
              -4.8,
              -7.5,
              -10.2,
              -12.3
            ]
          },
          {
            "name": "BMF-650, 30mg/kg",
            "unit": "%",
            "values": [
              -7.5,
              -10.7,
              -13.5,
              -15.2
            ]
          }
        ],
        "figure_id": "b4583fee6b0dae87",
        "provenance": {
          "page": 34
        }
      },
      {
        "type": "other",
        "title": "Clinical Trial Design for Icovemenib",
        "page": 36,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Eligibility Criteria",
              "Treatment Arms",
              "Primary Endpoints",
              "Secondary Endpoints",
              "Timeline"
            ]
          },
          "y": {
            "unit": null,
            "range": null
          }
        },
        "series": [
          {
            "name": "Planned Participants",
            "unit": "N",
            "values": [
              {
                "total": 216,
                "ratio": "3:1"
              }
            ]
          },
          {
            "name": "Eligibility Criteria",
            "unit": null,
            "values": [
              "Adults (18-65 years) with T2D (<7 years)",
              "HbA1c 7.0-10.5%",
              "BMI 25-40 kg/m2",
              "Treated with up to 3 antidiabetic agents (excluding insulin and SFUs)",
              "N=72 participants per arm (3:1 ratio, icovamenib: PBO)"
            ]
          },
          {
            "name": "Arm A (N=72)",
            "unit": null,
            "values": [
              "icovamenib x8 wks 100 mg (QD)",
              "Placebo x4 wks 100 mg (QD)"
            ]
          },
          {
            "name": "Arm B (N=72)",
            "unit": null,
            "values": [
              "icovamenib x12 wks 100 mg (QD)"
            ]
          },
          {
            "name": "Arm C (N=72)",
            "unit": null,
            "values": [
              "icovamenib x8 wks 100 mg (QD)",
              "icovamenib x4 wks 100 mg (BID)"
            ]
          },
          {
            "name": "Primary Endpoints",
            "unit": null,
            "values": [
              "Change of HbA1c from baseline at Week 26",
              "Safety and tolerability at Week 52"
            ]
          },
          {
            "name": "Secondary Endpoints",
            "unit": null,
            "values": [
              "Proportion of subjects achieving an HbA1c <7% at Week 26",
              "Measure of glycemic control (plasma glucose, c-peptide and insulin) at Week 26",
              "The β-cell function (HOMA-β and HOMA-IR) at Week 26"
            ]
          },
          {
            "name": "Timeline",
            "unit": null,
            "values": [
              "12-Week Treatment Period",
              "Follow up Period",
              "Week 26 Primary Endpoint (December 2024)",
              "Week 52 End of Study"
            ]
          }
        ],
        "figure_id": "4e5a35ceaf14cc49",
        "provenance": {
          "page": 36
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Biomea Fusion (BMEA) as of 08-27-2025",
        "page": 48,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "$",
            "range": {
              "min": 0,
              "max": 50
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "$",
            "values": [
              {
                "date": "2022-11-07",
                "value": 19.0,
                "annotation": "BUY"
              },
              {
                "date": "2023-03-28",
                "value": 36.0,
                "annotation": "BUY"
              },
              {
                "date": "2023-06-26",
                "value": 28.0,
                "annotation": "HOLD"
              },
              {
                "date": "2023-11-02",
                "value": 10.0,
                "annotation": "HOLD"
              }
            ]
          }
        ],
        "figure_id": "47cdf933c6b27487",
        "provenance": {
          "page": 48
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "82615025938279ee",
        "value": 1.69,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Y</td></tr><tr><td>PRICE</td><td>&#36;1.86*</td></tr><tr><td>PRICE TARGET|% TO PT</td><td>&#36;5.00|+169%</td></tr><tr><td>52W HIGH-LOW</td><td>&#36;13.07-&#36;1.29</td></tr><tr><td>FLOAT (%)|ADV MM (",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "95897d2ab05b3e68",
        "value": 0.677,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>52W HIGH-LOW</td><td>&#36;13.07-&#36;1.29</td></tr><tr><td>FLOAT (%)|ADV MM (USD)</td><td>67.7%|1.24</td></tr><tr><td>MARKET CAP</td><td>&#36;111.6M</td></tr><tr><td>TICKER</td><td>BMEA</td>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "771e6dee3badb5c2",
        "value": 750000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "y and evaluate their oral GLP- 1RA, BMF- 650 in obesity. We model peak adjusted revenues of \\(\\sim \\$ 750M\\) , driven by BMEA's T2D franchise. Thus, we initiate at Buy with PT of \\(\\) 5\\$ . Bottom lin",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "91baa73a2f1a717e",
        "value": 750000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "hts on key questions surrounding icovamenib's durability and long- term safety. We estimate \\(\\sim \\$ 750M\\) in peak adjusted revenues for the Icovamenib T2D program with \\(\\sim \\$ 100M\\) for BMEA's p",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0446f0603309054b",
        "value": 100000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "We estimate \\(\\sim \\$ 750M\\) in peak adjusted revenues for the Icovamenib T2D program with \\(\\sim \\$ 100M\\) for BMEA's platform/ pipeline. Co has \\(\\sim \\$ 60M\\) in cash with runway into 2H26. Rating/",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "503ee6922b1deadb",
        "value": 60000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "for the Icovamenib T2D program with \\(\\sim \\$ 100M\\) for BMEA's platform/ pipeline. Co has \\(\\sim \\$ 60M\\) in cash with runway into 2H26. Rating/ valuation. We initiate coverage with Buy rating and ha",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "3e264eb60fa71989",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Clinical data – efficacy vs approved Tx - Icovamenib's Ph2a HbA1c efficacy data of pbo-adj ~1.5% mean HbA1c reduction at week 26 is on par with that of most currently approved T2D therapies - Oze",
        "provenance": {
          "page": 20
        }
      },
      {
        "num_id": "2c7b4725debf516e",
        "value": -0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "most currently approved T2D therapies - Ozempic (GLP-1 agonist) has reported mean HbA1c change of -1.5% at its highest 1mg dose at week 30, Jardiance (SGLT2 inhibitor) has reported mean change of -0.9",
        "provenance": {
          "page": 20
        }
      },
      {
        "num_id": "1084398c02d477eb",
        "value": -0.009000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "f -1.5% at its highest 1mg dose at week 30, Jardiance (SGLT2 inhibitor) has reported mean change of -0.9% at highest 25mg dose at week 24, and Januvia (DPP4 inhibitor) has reported mean change of -0.8",
        "provenance": {
          "page": 20
        }
      },
      {
        "num_id": "16d4241f35a8b3da",
        "value": -0.008,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "of -0.9% at highest 25mg dose at week 24, and Januvia (DPP4 inhibitor) has reported mean change of -0.8% at 199mg dose at week 24 - Icovamenib is differentiated based on its disease-modifying MOA, its",
        "provenance": {
          "page": 20
        }
      },
      {
        "num_id": "fe21d72e94fc5468",
        "value": -0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>ICOVAMENIB (Menin Inhibitor)</td><td>12 Weeks</td><td>Oral</td><td>Week 26</td><td>-1.5% (100mg)</td></tr><tr><td>Ozempic (GLP 1 Agonist)</td><td>Chronic Dosing</td><td>Injectable</td",
        "provenance": {
          "page": 20
        }
      },
      {
        "num_id": "6d25d3f3e9109c62",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "023 </center> ![Figure 27-1](images/27_1.jpg) <center>Mean Time to Loss of Glucose Control (HbA1c>7%) </center> <center>Nathan et al. N Engl J Med 2022 </center><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "96546aceee6c477f",
        "value": 750000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "market and \\(15\\%\\) estimated POS, we expect icovamenib to generate adjusted peak sales of \\(\\sim \\$750M\\)<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "e824ecb1d5350b0a",
        "value": 0.008,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "10 pts with HbA1c uncontrolled despite on background GLP-1R-based therapy saw clinically meaningful 0.8% reduction in HbA1c and additional weight loss after initiating icovamenib of up to 14% at week ",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "8a28dd20ca2a55bb",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "meaningful 0.8% reduction in HbA1c and additional weight loss after initiating icovamenib of up to 14% at week 26 - Co expects to start a Ph2 in 2H25 ## Icovamenib's Effect In Combination with Semaglu",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "9c8a52171081eecf",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ction in obese cynomolgus monkeys through week 4 - At low dose tested (10mg/kg) BMF-650 achieved a 12% reduction in average weight while at the high dose tested (30mg/kg), BMF-650 achieved a 15% reduc",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "6fb5cb153aa07b11",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ieved a 12% reduction in average weight while at the high dose tested (30mg/kg), BMF-650 achieved a 15% reduction - Co is currently wrapping up IND enabling studies and expects to enroll the first cli",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "dd4a0a4bf3c246fe",
        "value": 58600000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ded with cash and cash equivalents, supporting operations into 2H26 - As of June 30, 2025, Co had \\$58.6M of cash, cash equivalents, and short-term investments - Total R&D expenses for the second quar",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "a7e5f8911afae668",
        "value": 16600000.000000002,
        "unit": "$",
        "metric_type": "currency",
        "context": "equivalents, and short-term investments - Total R&D expenses for the second quarter of 2025 were \\$16.6M, compared to \\$31.8M for the second quarter of 2024. This decrease was primarily due to decreas",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "17cc3bff5f92abbc",
        "value": 31800000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "rt-term investments - Total R&D expenses for the second quarter of 2025 were \\$16.6M, compared to \\$31.8M for the second quarter of 2024. This decrease was primarily due to decreased personnel-related",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "5110a2c9a3c598c4",
        "value": 31800000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ical, and exploratory programs - Total SG&A for the second quarter of 2025 was -16.6M compared to \\$31.8M for the second quarter of 2024. - Co anticipates future quarterly operational expenses to be \\",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "fb998ca3275d87d7",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "50 $358 $469 $473 $478 $484 $490 $497</td></tr><tr><td>NPV of Cash Flows 2026E - 2045E</td><td>$206 12%</td></tr><tr><td>Platform/ pipeline/ partnership Value</td><td>$100</td></tr><tr><td>Enterprise ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "0276fda88b3fe004",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2025E 2026E 2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><t",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "18a2a6edb0fae0f8",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "25E 2026E 2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "d8426d6826c2ae89",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2026E 2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Oper",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "1d7b4f59931ded7b",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "26E 2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operat",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "ae2d600d77bf8faa",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "274dee3ab09e3ad4",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "27E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating ex",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "b6d1fb9e06ee8841",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expens",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "c25b28d65307a524",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "28E 2029E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "4b8ba05b06a77b66",
        "value": 4.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2029E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "91e17ed9071db6b2",
        "value": 56.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "29E 2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "d696e5b52003aeff",
        "value": 114.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2030E 2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "592ab72bdc98548d",
        "value": 181.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2031E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $1",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "e7b3e599f3a6393d",
        "value": 315.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "E 2032E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "cdf34f35b9aec8ee",
        "value": 392.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2E 2033E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $9",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "fdd78b53d1134712",
        "value": 538.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "33E 2034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "b44532d2fd4cf449",
        "value": 687.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "034E 2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "04ef15f14d0dd5d8",
        "value": 695.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2035E</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "4001c7cab0f8fb4c",
        "value": 703.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td></tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "d2ba4c92ca1a0d4e",
        "value": 713.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</tr><tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "6211e5fb0f2b3de2",
        "value": 723.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "<tr><td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "f5fce4d7247b730a",
        "value": 735.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>Revenue</td><td>$0 $0 $0 $0 $0 $0 $0 $0 $4 $56 $114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "2a72956f94e2adab",
        "value": 126.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$114 $181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "0009b98d3e051f1f",
        "value": 144.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$181 $315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "094ca29071c5bb83",
        "value": 87.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$315 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "b5bda169b5f29054",
        "value": 91.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "5 $392 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "5a40bd9f6c77a139",
        "value": 96.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "92 $538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "5e6223c83fa8af1d",
        "value": 100.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "538 $687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "b74b623db67a97d2",
        "value": 104.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "687 $695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT<",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "fdf0b3d45f839e88",
        "value": 109.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "695 $703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "09e09c5b0ad24063",
        "value": 114.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "703 $713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "8d594bc956f808ef",
        "value": 119.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "713 $723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "936cfa56ddc34006",
        "value": 48.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "723 $735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "5c06f37d6b4da937",
        "value": 61.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$735</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "f2b8fc870eebb6b1",
        "value": 66.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "a30434bb9210dedc",
        "value": 71.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "></tr><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "3b0adde64ac235b3",
        "value": 79.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "r><tr><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "cd11d069745b06de",
        "value": 85.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "r><td>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "b14c5a111343127b",
        "value": 94.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>Operating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($10",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "62d878bc833bbe79",
        "value": 104.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "erating expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) (",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "fc9dc467f56dc8a8",
        "value": 106.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ng expenses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104)",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "50c2cb84f5e64458",
        "value": 109.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "penses</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104) ($10",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "ae8182191dd64249",
        "value": 112.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "s</td><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "86ee4570160879e5",
        "value": 114.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($114) ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "f36c70c48205e196",
        "value": 117.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$126 $144 $87 $91 $96 $100 $104 $109 $114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($114) ($119",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "c81675745bf448c8",
        "value": 126.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$114 $119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($114) ($119) ($44) ($55) $49 $110 $236 $306 $444",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "0a5f209511ed8136",
        "value": 144.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "119 $48 $61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($114) ($119) ($44) ($55) $49 $110 $236 $306 $444 $583 ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "e7bc9f3b28d27cb1",
        "value": 87.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$61 $66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($114) ($119) ($44) ($55) $49 $110 $236 $306 $444 $583 $588 $59",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "d149fa5a883a40a5",
        "value": 91.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "66 $71 $79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($114) ($119) ($44) ($55) $49 $110 $236 $306 $444 $583 $588 $594 $60",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "2900ad8901cfd744",
        "value": 96.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$79 $85 $94 $104 $106 $109 $112 $114 $117</td></tr><tr><td>EBIT</td><td>($126) ($144) ($87) ($91) ($96) ($100) ($104) ($109) ($114) ($119) ($44) ($55) $49 $110 $236 $306 $444 $583 $588 $594 $601 $609 ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "4166e689b2a67f34",
        "value": 176.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cash and cash equivalents</td><td></td><td>$176.9</td><td>$58.3</td><td>$20.6</td><td>$148.7</td><td>$64.3</td><td>$276.0</td><td>$183.7</td><t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "2fb8cbefac92efc4",
        "value": 58.3,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td></td><td></td><td></td></tr><tr><td>Cash and cash equivalents</td><td></td><td>$176.9</td><td>$58.3</td><td>$20.6</td><td>$148.7</td><td>$64.3</td><td>$276.0</td><td>$183.7</td><td>$487.1</td></",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "5c74312d5c5db707",
        "value": 20.6,
        "unit": "$",
        "metric_type": "currency",
        "context": "></td><td></td></tr><tr><td>Cash and cash equivalents</td><td></td><td>$176.9</td><td>$58.3</td><td>$20.6</td><td>$148.7</td><td>$64.3</td><td>$276.0</td><td>$183.7</td><td>$487.1</td></tr><tr><td>Mar",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "d04a3cd2f8d82624",
        "value": 148.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "></tr><tr><td>Cash and cash equivalents</td><td></td><td>$176.9</td><td>$58.3</td><td>$20.6</td><td>$148.7</td><td>$64.3</td><td>$276.0</td><td>$183.7</td><td>$487.1</td></tr><tr><td>Marketable securi",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "94db9296497cd020",
        "value": 64.3,
        "unit": "$",
        "metric_type": "currency",
        "context": "ash and cash equivalents</td><td></td><td>$176.9</td><td>$58.3</td><td>$20.6</td><td>$148.7</td><td>$64.3</td><td>$276.0</td><td>$183.7</td><td>$487.1</td></tr><tr><td>Marketable securities and invest",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "3c2b012f57f617b8",
        "value": 276.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "quivalents</td><td></td><td>$176.9</td><td>$58.3</td><td>$20.6</td><td>$148.7</td><td>$64.3</td><td>$276.0</td><td>$183.7</td><td>$487.1</td></tr><tr><td>Marketable securities and investment</td><td><",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "06a6862c7fe995c7",
        "value": 183.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td><td>$176.9</td><td>$58.3</td><td>$20.6</td><td>$148.7</td><td>$64.3</td><td>$276.0</td><td>$183.7</td><td>$487.1</td></tr><tr><td>Marketable securities and investment</td><td></td><td>$0.0</t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "f4f1f579cb981426",
        "value": 487.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "76.9</td><td>$58.3</td><td>$20.6</td><td>$148.7</td><td>$64.3</td><td>$276.0</td><td>$183.7</td><td>$487.1</td></tr><tr><td>Marketable securities and investment</td><td></td><td>$0.0</td><td>$0.0</td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "2ef1972c37de3b6a",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$183.7</td><td>$487.1</td></tr><tr><td>Marketable securities and investment</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.1</td></tr",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "114467b89a9eeac3",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$487.1</td></tr><tr><td>Marketable securities and investment</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.1</td></tr><tr><td>Acco",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "f18df24e71d60ad0",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ".1</td></tr><tr><td>Marketable securities and investment</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.1</td></tr><tr><td>Accounts receivab",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "392a6b3bafa1b4a9",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "tr><td>Marketable securities and investment</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.1</td></tr><tr><td>Accounts receivable</td><td></",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "03b484ca044aa86e",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "rities and investment</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.1</td></tr><tr><td>Accounts receivable</td><td></td><td>$0.0</td><td>$0",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "15ae2fd473560a6d",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "vestment</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.1</td></tr><tr><td>Accounts receivable</td><td></td><td>$0.0</td><td>$0.0</td><td>$0",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "d9078593f4959c8d",
        "value": 0.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.1</td></tr><tr><td>Accounts receivable</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "9d82406bc7fa6e05",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td></td><td>$0.0</td><td>$0.0</td><td>$0.1</td></tr><tr><td>Accounts receivable</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.2</td></tr",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "3207735a1ea2fe52",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>$0.0</td><td>$0.0</td><td>$0.1</td></tr><tr><td>Accounts receivable</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.2</td></tr><tr><td>Inve",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "18f4791d11ded50b",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>$0.0</td><td>$0.1</td></tr><tr><td>Accounts receivable</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.2</td></tr><tr><td>Inventory</td><td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "2eec8b34a84ff75b",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>$0.1</td></tr><tr><td>Accounts receivable</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.2</td></tr><tr><td>Inventory</td><td></td><td>$0.",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "46057f69a7eadb09",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>Accounts receivable</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.2</td></tr><tr><td>Inventory</td><td></td><td>$0.0</td><td>$0.0</td><td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "353c217a5bf931b9",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ceivable</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.2</td></tr><tr><td>Inventory</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "e974a585160d2c2a",
        "value": 0.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.2</td></tr><tr><td>Inventory</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "78289d1bde0e0e78",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.2</td></tr><tr><td>Inventory</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.3</td></tr",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "cbb5e4906ec0200c",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td></td><td>$0.0</td><td>$0.0</td><td>$0.2</td></tr><tr><td>Inventory</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.3</td></tr><tr><td>Prep",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "2cf1e6306028ab9c",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "0.0</td><td>$0.0</td><td>$0.2</td></tr><tr><td>Inventory</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.3</td></tr><tr><td>Prepaid expenses ",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "15be1fab8f520b8d",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "0.0</td><td>$0.2</td></tr><tr><td>Inventory</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.3</td></tr><tr><td>Prepaid expenses and other cur",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "d7e01f018d0d160c",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/tr><tr><td>Inventory</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.3</td></tr><tr><td>Prepaid expenses and other current assets</td><td></",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "d779792d64656a5a",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "nventory</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.3</td></tr><tr><td>Prepaid expenses and other current assets</td><td></td><td>$2.3</",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "60c46752d78542fc",
        "value": 0.3,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.3</td></tr><tr><td>Prepaid expenses and other current assets</td><td></td><td>$2.3</td><td>$10.1<",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "1bd8847d838e26b4",
        "value": 2.3,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$0.0</td><td>$0.3</td></tr><tr><td>Prepaid expenses and other current assets</td><td></td><td>$2.3</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td></td><td>$10.1</td><td>$10.1</t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "6a23a6a5687cec35",
        "value": 10.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$0.3</td></tr><tr><td>Prepaid expenses and other current assets</td><td></td><td>$2.3</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td></td><td>$10.1</td><td>$10.1</td></tr><tr><t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "a218f5aedb312433",
        "value": 10.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "></tr><tr><td>Prepaid expenses and other current assets</td><td></td><td>$2.3</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td></td><td>$10.1</td><td>$10.1</td></tr><tr><td>Other curren",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "850b83c1abb934df",
        "value": 10.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "Prepaid expenses and other current assets</td><td></td><td>$2.3</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td></td><td>$10.1</td><td>$10.1</td></tr><tr><td>Other current Assets</td><",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "dd0a9f5f1c6f08b9",
        "value": 10.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "es and other current assets</td><td></td><td>$2.3</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td></td><td>$10.1</td><td>$10.1</td></tr><tr><td>Other current Assets</td><td></td><td>$0",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "afcca3b8017600d9",
        "value": 10.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "sets</td><td></td><td>$2.3</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td></td><td>$10.1</td><td>$10.1</td></tr><tr><td>Other current Assets</td><td></td><td>$0.0</td><td>$0.0</td><td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "6a0db2f5d0abbae0",
        "value": 10.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$2.3</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td>$10.1</td><td></td><td>$10.1</td><td>$10.1</td></tr><tr><td>Other current Assets</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "a972c067b8ff3403",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>$10.1</td><td></td><td>$10.1</td><td>$10.1</td></tr><tr><td>Other current Assets</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.4</td></tr",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "e5ef7331248f207c",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td></td><td>$10.1</td><td>$10.1</td></tr><tr><td>Other current Assets</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.4</td></tr><tr><td>Tota",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "d4e172f977293751",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "10.1</td><td>$10.1</td></tr><tr><td>Other current Assets</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.4</td></tr><tr><td>Total Current Ass",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "cdd31e67dcb9ddb2",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$10.1</td></tr><tr><td>Other current Assets</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.4</td></tr><tr><td>Total Current Assets</td><td><",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "19934965693f9140",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ">Other current Assets</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.4</td></tr><tr><td>Total Current Assets</td><td></td><td>$179.2</td><td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "053ee4555be1093a",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "t Assets</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.4</td></tr><tr><td>Total Current Assets</td><td></td><td>$179.2</td><td>$68.3</td><t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "1ac852ce06178033",
        "value": 0.4,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td>$0.0</td><td></td><td>$0.0</td><td>$0.0</td><td>$0.4</td></tr><tr><td>Total Current Assets</td><td></td><td>$179.2</td><td>$68.3</td><td>$30.6</td><",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "e13fe0f4f6b2875a",
        "value": 179.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td></td><td>$0.0</td><td>$0.0</td><td>$0.4</td></tr><tr><td>Total Current Assets</td><td></td><td>$179.2</td><td>$68.3</td><td>$30.6</td><td>$158.7</td><td>$74.3</td><td>$286.0</td><td>$193.7</td><t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "3f05f9087a4a9794",
        "value": 68.3,
        "unit": "$",
        "metric_type": "currency",
        "context": "0.0</td><td>$0.0</td><td>$0.4</td></tr><tr><td>Total Current Assets</td><td></td><td>$179.2</td><td>$68.3</td><td>$30.6</td><td>$158.7</td><td>$74.3</td><td>$286.0</td><td>$193.7</td><td>$497.2</td></",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "1b78f5e010a4a7ad",
        "value": 30.6,
        "unit": "$",
        "metric_type": "currency",
        "context": ".0</td><td>$0.4</td></tr><tr><td>Total Current Assets</td><td></td><td>$179.2</td><td>$68.3</td><td>$30.6</td><td>$158.7</td><td>$74.3</td><td>$286.0</td><td>$193.7</td><td>$497.2</td></tr><tr><td>Pro",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "d703c166d92bace8",
        "value": 158.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "4</td></tr><tr><td>Total Current Assets</td><td></td><td>$179.2</td><td>$68.3</td><td>$30.6</td><td>$158.7</td><td>$74.3</td><td>$286.0</td><td>$193.7</td><td>$497.2</td></tr><tr><td>Property and equi",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "c9c4471a63ccb627",
        "value": 74.3,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>Total Current Assets</td><td></td><td>$179.2</td><td>$68.3</td><td>$30.6</td><td>$158.7</td><td>$74.3</td><td>$286.0</td><td>$193.7</td><td>$497.2</td></tr><tr><td>Property and equipment, net</td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "8b81c0f3433e2f58",
        "value": 286.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ent Assets</td><td></td><td>$179.2</td><td>$68.3</td><td>$30.6</td><td>$158.7</td><td>$74.3</td><td>$286.0</td><td>$193.7</td><td>$497.2</td></tr><tr><td>Property and equipment, net</td><td></td><td>$",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "d19c069bd9cb3a9c",
        "value": 193.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td><td>$179.2</td><td>$68.3</td><td>$30.6</td><td>$158.7</td><td>$74.3</td><td>$286.0</td><td>$193.7</td><td>$497.2</td></tr><tr><td>Property and equipment, net</td><td></td><td>$5.2</td><td>$3.",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "a647224a05d8489f",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "consistently below \\(10, the expected total return (price appreciation plus yield) is plus or minus 20% within a 12-month period. For Underperform rated securities with an average security price consi",
        "provenance": {
          "page": 47
        }
      },
      {
        "num_id": "48c1dbf62172e951",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "y price consistently below\\) 10, the expected total return (price appreciation plus yield) is minus 20% or less within a 12-month period. NR - The investment rating and price target have been temporar",
        "provenance": {
          "page": 47
        }
      },
      {
        "num_id": "c25a7fe8b7d4b82c",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent",
        "provenance": {
          "page": 47
        }
      },
      {
        "num_id": "c7bec44e47fb8e0a",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not ",
        "provenance": {
          "page": 47
        }
      },
      {
        "num_id": "faebb82d484bd47c",
        "value": 0.6069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Percent</td><td>Count</td><td>Percent</td><td>Count</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><",
        "provenance": {
          "page": 48
        }
      },
      {
        "num_id": "d8c39114c095ff80",
        "value": 0.17379999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Percent</td><td>Count</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><",
        "provenance": {
          "page": 48
        }
      },
      {
        "num_id": "b1198cec8a1eecbc",
        "value": 0.0554,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "unt</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td",
        "provenance": {
          "page": 48
        }
      },
      {
        "num_id": "9106feecb9070667",
        "value": 0.348,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157<",
        "provenance": {
          "page": 48
        }
      },
      {
        "num_id": "a2e5cd0751bbcf78",
        "value": 0.0867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td",
        "provenance": {
          "page": 48
        }
      },
      {
        "num_id": "5f2b4f56db250853",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td>",
        "provenance": {
          "page": 48
        }
      },
      {
        "num_id": "88a8a884403d20b2",
        "value": 0.0451,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 48
        }
      },
      {
        "num_id": "b0cf3bc5c2e66a07",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 48
        }
      },
      {
        "num_id": "7874091be3804cf6",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 48
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 21,
      "tables_count": 0,
      "numerical_data_count": 134,
      "passages_count": 217,
      "entities_count": 20
    }
  }
}